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Abstract 
 
Background: Chronic kidney disease (CKD) affects approximately 20 million Americans and is 
the cause of significant morbidity and mortality. Anemia, common in CKD, develops early in the 
disease process. It contributes to increased risk of cardiovascular disease, hospitalization, 
mortality, and diminishes health-related quality of life. Intravenous iron and Erythropoiesis 
Stimulating Agents (ESAs) are recommended for anemia management in CKD. The utilization 
patterns of IV iron and ESA, and their impact on hospital costs and length of stay merits 
investigation.  
 
Objectives: There were five general objectives of this investigation. The rate and extent of 
utilization of IV iron in anemic CKD patients was quantified across teaching hospitals in the US. 
Patient characteristics of those receiving IV iron and ESA and ESA alone were evaluated in 
detail. Predictors of IV iron and ESA use were determined. The impact of IV iron and ESA use 
was examined separately for total hospital costs and length of stay (LOS) while adjusting for 
confounding. 
 
Methods: This is a retrospective cohort analysis within the University Health System 
Consortium data warehouse. Eligible patients are those who were admitted to a hospital and 
received either IV iron and ESA or both at least once during the period of January 1, 2006, and 
December 31, 2008. Inclusion criteria include age > 18 years old with a primary or secondary 
diagnosis of CKD. The exposure of interest was IV iron and ESA therapy, and the outcome was 
the difference in total hospital costs and length of stay between patients only on ESA, and those 
on ESA and IV iron. A clustered binomial logistic regression using the GEE methodology was 
 x 
 
used to identify predictors of IV iron utilization. Propensity scores were used to control for 
confounding. A generalized estimating equations (GEE) model using a gamma distribution and 
log link was used to determine the adjusted hospital cost and length of stay for the IV iron and 
ESA and ESA alone therapy groups.  
 
Results: During the study period, 82,947 patients met all the inclusion and exclusion criteria. Of 
the 82,947 CKD patients on ESA therapy, only 8% (n = 6678) patients were on IV iron 
supplementation. Age, race, primary payer, admission status, severity of illness, dialysis status 
and physician specialty were identified as strong predictors of IV iron use in CKD patients. 
According to the multivariate model, the overall mean hospital cost for all 82,947 patients was 
$31,674. For patients using both IV iron and ESA (n=6678), mean costs were $34,756 compared 
to $31,404 for ESA users alone (n=76,269) – a difference of $3,352. The overall mean LOS for 
all patients was 9.75 days. For those using IV iron, the LOS was 10.71 days, and for those only 
using ESA, the LOS was 9.66 days– a difference of approximately 1 day.  
 
Conclusions: This inquiry is the first large multi-center investigation to quantify the impact of 
IV iron and ESA use on total hospital costs and LOS. Our investigation showed significant 
reduction in ESA doses with the use of IV iron supplementation, however, the overall prevalence 
of IV iron usage was low. Intravenous iron users were associated with a higher total hospital cost 
and longer length of stay than ESA users.
 1 
 
CHAPTER 1 
 
Introduction 
 
Overview of the document 
 
This dissertation describes a study designed to quantify the rate and extent of IV iron and ESA 
utilization in anemic CKD patients and quantify the differences in LOS and total hospital costs 
resulting from the utilization of IV iron and ESA and ESA therapy-alone. This chapter provides 
background information necessary to understand the significance of the project. The second 
chapter systematically reviews the available literature and provides more extensive background 
on previous investigations, economic issues and confounding factors. Chapter 3 describes the 
methodology used for the dissertation project. The results are provided in Chapter 4, followed by 
a discussion and concluding remarks in Chapter 5. 
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Background 
 
Chronic kidney disease (CKD) is a worldwide public health issue.
2
 In the United States, 
CKD affects approximately 20 million Americans and is the cause of significant morbidity and 
mortality in 1 in 9 adults.
3
 According to a recent US Renal Data System Annual Data Report, the 
percent growth in Medicare patients was greatest in CKD (128%) and end stage renal disease 
(ESRD) (83%) when compared with diabetes mellitus (54%) and chronic heart failure (21%).
4
 
The national initiative, Healthy People 2010, identified CKD as one of the areas to focus on in an 
effort to reduce the number of patients reaching ESRD, and decrease health care costs within 
Medicare.
5
 The prevalence of earlier stages of CKD is approximately 100 times greater than the 
prevalence of kidney failure, affecting almost 11% of adults in the United States.
2,6
 
Patients with CKD often have 5 to 6 other conditions which require extensive therapeutic 
treatment. Common comorbidities include anemia, diabetes mellitus, hypertension and coronary 
artery disease.
7, 8
 Anemia, common in CKD, develops early in the disease process and 
contributes to a poor quality of life in this population. The PAERI (Prevalence of Anemia in 
Early Renal Insufficiency) study reported an overall anemia prevalence of 47%, increasing from 
26.7% in patients with Stage 1 CKD to 75.5% in those with Stage 5 CKD who are not on 
dialysis.
9
 Anemia of CKD results from underproduction of endogenous erythropoietin by the 
kidneys.
10
 In patients with CKD not requiring dialysis, untreated anemia increases cardiovascular 
risk, hospitalization,
11
 and all-cause mortality, 
12
 impaired cognitive function
3
, and diminishes 
health-related quality of life 
13
 and exercise capacity.
14, 15
 Heightened risk for progression of 
kidney failure has also been linked to untreated anemia of CKD. Thus, management of anemia 
throughout the CKD continuum is essential.
16-18
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The recombinant human erythropoietin, epoetin alfa (EPO), introduced in 1989, was the 
first erythropoiesis-stimulating agent (ESA) available for the treatment of anemia in the United 
States. The availability of ESAs substantially reduced the need for transfusions and became the 
first line of therapy for anemia of CKD.
19
 Epoetin alfa, which must be injected 2 to 3 times per 
week to achieve efficacy, remained the only exogenous ESA for more than a decade. Although 
ESAs can be beneficial in treating patients with anemia of CKD, they have inherent risks. 
Randomized trials in patients undergoing dialysis have found higher rates of cardiovascular 
complications with higher (13-15 g/dl) versus lower (10-11.5 g/dl) Hb targets.
20-22
 Increased risk 
of adverse events, such as cardiovascular complications,
23, 24
 hypertension 
25
 and pure red cell 
aplasia,
26
 have been reported with the use of ESAs. The U.S. Food and Drug Administration 
(FDA) recently amended the labeling of all epoetin and darbepoetin products by adding a boxed 
warning instructing prescribers to use the lowest dose of ESAs that will gradually increase the 
hemoglobin concentration to the lowest level sufficient to avoid the need for red blood cell 
transfusion.
27
 Also, the FDA recently stated that all ESAs prescribed must be a part of the Risk 
Evaluation and Mitigation Strategies (REMS) program to ensure the safe use of these drugs.
28
 
Hence, minimizing the dose of ESAs may be beneficial for patients. Besides the clinical issues, 
there are several economic challenges associated with the use of ESAs. The approximate annual 
cost of EPO is estimated to be about $5,000.
29
 ESAs are considered specialty pharmaceuticals 
and usually have the highest co-pay allocation (Tier 4). They may require prior authorization and 
may have quantity limits in place. Medicare Part B covers ESAs for eligible patients but only 
when doses are administered in the physician‟s office or clinic. Patients who self-administer ESA 
are not covered by Medicare Part B.  
 4 
 
Iron deficiency occurs in most patients during therapy with ESAs because of the increase 
in erythropoiesis and subsequent increase in iron demand. Iron is the core raw material for the 
production of red blood cells (RBCs). Without iron, hemoglobin can be neither synthesized nor 
can RBCs be reproduced or maintained in the circulation at an adequate level. Optimal red cell 
production requires both erythropoietin as the controlling factor and iron as the raw material.
30
 
Deficiency can occur in all patients, even those with initially adequate stores of iron because the 
rate of iron supply cannot meet the demands of accelerated erythropoiesis. Iron supplementation 
should therefore be considered for all patients, and iron status should be closely monitored. 
According to the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative 
(NKF-KDOQI) guidelines, it is suggested that supplemental iron be administered intravenously 
in hemodialysis dependent CKD patients.
31
 Non-dialysis-dependent CKD patients and peritoneal 
dialysis dependent CKD patients may receive iron orally or intravenously.
31
 Ongoing 
administration of parenteral iron preserves levels of hemoglobin and reduces the requirement for 
administration of erythropoietin.
32-34
 Given the relative costs of iron and erythropoietin, an 
appropriate use of iron can have substantial cost savings. Moreover, considering the adverse 
event profile of erythropoietin, reduction in its dose and ongoing administration of parenteral 
iron can help improve survival rate and quality of life for CKD patients.  
The current literature suggests the need to further evaluate the medication utilization 
patterns of IV iron in anemic CKD patients, and understand its impact on hospital resource use 
and total hospital costs. There is currently no evidence in the literature comparing the long term 
utilization of IV iron and ESA, and their economic impact on hospital costs and LOS. A careful 
analysis of utilization patterns and economic impact of the recommended treatment options for 
anemic CKD patients is necessary in determining the optimal care that could be provided to the 
 5 
 
patient. The cost and resource use of providing such care should be considered in order to either 
validate or cause the health care provider to reconsider a selected pharmacological treatment. 
This investigation looks to quantify the rate and extent of IV iron and ESA utilization in anemic 
CKD patients and quantify the differences in LOS and total hospital costs resulting from the 
utilization of IV iron and ESA and ESA therapy-alone.  
An economic analysis of drug and resource use requires further explanation in order to 
ensure correct interpretation. For example, the terms costs and charges must be clearly defined 
and their difference be explicitly stated.  These terms may have been used interchangeably, but 
this is incorrect. Costs and charges reflect different economic values. Specifically, charges 
always over-inflate cost.
35
  For the purposes of this report, great care has been given to use the 
terms costs and charges appropriately. Previous investigations have used costs or charges as 
outcomes depending on study design and data availability. The economic background section 
provides a more thorough discussion of costs versus charges. 
A pharmacoepidemiologic investigation attempting to describe the relationship between 
an exposure and outcomes must consider potential confounders. Confounding factors are 
variables that are associated with the outcome as well as the exposure, and are not variables in 
the causal pathway. If confounding exists, an association may appear to be present when one 
does not exist or there may seem to be no association when a true association does exist.
36
 
Therefore, it is crucial to identify confounders and control for them. In most situations 
confounders are identified a priori based on previous investigations or expert opinion.
37
 Several 
variables have been acknowledged as potential confounders in the relationship between drug use 
and total costs in anemia in chronic kidney disease. Specifically, patient demographics (age, 
race, sex), underlying severity of illness, dialysis status, drug insurance coverage type, physician 
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specialty, mortality and comorbid conditions, have been identified.
7,11,38-43
 Hospital level factors 
(e.g. bed size, geographic location) can also confound the relationship between drug utilization 
and total cost.  
 Propensity scores are another way to control for confounding. Observational studies 
employ this method to eliminate bias from an unequal distribution of confounders thereby 
mimicking the purpose of randomization in a randomized, controlled clinical trial. Propensity 
scores are the probability of exposure given measured baseline variables.
44
 This probability can 
then be used as a matching or stratification factor, as a covariate in a multivariable model or to 
perform inverse probability of exposure weighting.
45
 
Long term IV iron usage and resultant hospital costs and outcomes remain untested. 
There has been a single previous investigation attempting to report the trends in IV iron use 
among US Medicare dialysis patients.
46
 The study reported an increase in the use of IV iron in 
ESRD patients from 1997 to 2002. Ferric gluconate and iron sucrose were reported as the 
predominant form of therapy in this population. Racial and geographical variability were 
observed in overall IV iron usage in the United States.
46
 From an economic perspective, Pizzi et 
al demonstrated that the administration of IV iron in conjunction with ESA is more cost-effective 
as compared to ESA therapy alone in anemic dialysis patients.
47
 Clinical inputs for this study 
were obtained from the DRIVE I 
48
 and DRIVE II 
49
 studies, and cost inputs were estimated 
based on published sources of Medicare reimbursement rates for dialysis services. Use of IV iron 
represented a net-savings of $1390 per g/100 ml increase in Hb over a 12 week period.
47
 Two 
single center investigations evaluated the potential economic benefit of IV iron in hemodialysis 
patients. Sepandj et al. projected an annual cost reduction of $3016 Canadian dollars in chronic 
dialysis patients (n = 50).
50
 Bhandari et al. evaluated the economic benefit of IV iron in 22 
 7 
 
hemodialysis patients. Use of IV iron led to reduced requirements of ESA, and hence resulted in 
cost-savings of £21/week.
51
  
Objectives 
The current investigation has four primary objectives which are listed below. 
1. Quantify the utilization of IV iron in chronic kidney disease patients across teaching 
hospitals in the US 
2. Determine the prevalence of concomitant IV iron administration when Erythropoiesis 
Stimulating Agents (ESA) therapy is initiated 
3. Determine predictors of IV iron use among the domains of patient characteristics, clinical 
conditions, physician characteristics, hospital characteristics and treatment characteristics.  
4. Determine the impact of IV iron and ESA use versus ESA use alone on length of stay 
(LOS) while adjusting for confounders 
5. Determine the impact of IV iron and ESA use versus ESA use alone on total hospital 
costs while adjusting for confounders 
 
Significance and practical implications  
A large national database of academic medical centers will be used to ascertain the 
medication utilization patterns in anemic CKD patients. Knowledge of their anemia medication 
use patterns may highlight practices that are at odds with current recommendations and identify 
opportunities to improve care. Identification of anemia treatment patterns in national academic 
centers may also assist evidence-based policy making by understanding the variations in 
physician prescriptions for CKD and reason for such variation. 
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The scientific community and healthcare professionals have acknowledged the 
importance of understanding the utilization of IV iron supplementation and its impact on health 
care costs and outcomes in hospitalized patients.
52
 Understanding the financial implications 
associated with IV iron use will equip hospitals and healthcare professionals to make informed 
decisions to better manage anemia in CKD patients.   
The proposed investigation will be the first to study anemia management in CKD patients 
and its impact on total hospital costs and LOS, using data from multiple academic hospitals. A 
couple of single center reports have been published studying utilization of IV iron and its impact 
on costs.
50, 51
 These investigations agree that use of IV iron along with ESA have near optimal 
outcomes in anemic patients with chronic kidney disease and lead to lower costs. Several 
randomized clinical trials have established the safety and efficacy of IV iron in anemic CKD 
patients. 
48, 49, 53
 However, long term usage of IV iron remains untested by randomized trials. A 
single previous investigation report the trends of IV iron use among US Medicare dialysis 
patients. 
46
 This study did not evaluate the economic impact of IV iron utilization. From an 
economic perspective, Pizzi et al demonstrated through a literature based decision-analytic 
model that the administration of IV iron in conjunction with ESA is more cost-effective as 
compared to ESA-alone therapy in anemic dialysis patients. 
47
 Clinical inputs for this study were 
obtained from the DRIVE studies, 
48,49
 hence results of this study may not be generalizable to 
clinical practice.  
A large multi-center investigation may help to quantify the economic impact of IV iron 
utilization in anemic chronic kidney disease patients. Interesting utilization patterns of IV iron 
and ESA therapies in multiple hospitals across the nation will provide a relatively clear picture of 
the medication profile and resulting economic impact in anemic CKD patients. The proposed 
 9 
 
investigation should have greater external validity than previous studies. Data from forty 
teaching hospitals will be considered making it a large multi-center investigation. A multi-center 
investigation will provide a larger sample size than previous single center reports.  
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CHAPTER 2 
 
Literature review 
 
 
This chapter has been divided into five parts: 1) an overview of anemia in CKD, 2) 
pharmacological treatment associated with anemia of CKD, 3) economic background from a 
hospital costs perspective, 4) confounding factors and methods to control for confounding, and 
5) a systematic review of existing studies. This chapter will be concluded with a summary and 
the research hypotheses formulated as a result of the literature evaluation. 
 
CKD anemia overview 
 
Chronic Kidney Disease 
Chronic kidney damage is defined as structural abnormalities of the kidney that can lead to 
decreased kidney function. The level of glomerular filtration rate (GFR) is accepted as the best 
measure of overall kidney function in health and disease. 
The NKF-KDOQI work group has defined CKD as: 
1.  Kidney damage for 3 or more months, as defined by structural or functional 
abnormalities of the kidney, with or without decreased glomerular filtration rate (GFR) 
manifest by either 
a. Pathological abnormalities; or 
b. Markers of kidney damage, including abnormalities in the composition of the 
blood or urine, or abnormalities in imaging tests 
2. GFR < 60 ml/min/1.73m2 for  ≥ 3 months, with or without kidney damage.  
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Until 2002, a common staging system for CKD did not exist and numerous terms were used 
to describe it. In 2002, the NKF-KDOQI developed a staging system (Table 1). CKD is now 
defined according to the presence or absence of kidney damage and level of kidney function- 
regardless of the patient‟s underlying diagnosis. KDOQI designates 5 stages, with stage 5 being 
End Stage Renal Disease (ESRD), when loss of kidney function precipitates a need for dialysis 
or kidney transplant. Patients in stages 1 and 2 may have robust, normal, or slightly lowered 
GFR with evidence of underlying kidney damage, including proteinuria; large or small kidneys 
on an ultrasound; or other evidence of compromised function. All people with GFR < 60 
ml/min/1.73m
2
 for more than 3 months are classified as having CKD. This classification 
represents a loss of 50% or more of the adult level of normal kidney function.
6
 Additionally, all 
people with kidney damage are classified as having CKD regardless of their GFR.
6
  
Table 2.1: Classification of CKD 
Stage Description GFR (ml/min/1.73m
2
) 
1 Kidney damage with normal GFR ≥ 90 
2 Kidney damage with mild decrease in GFR 60-89 
3 Moderate decrease in GFR 30-59 
4 Severe decrease in GFR 15-29 
5 Kidney failure (dialysis or replacement needed) 
End Stage Renal Disease (ESRD) 
< 15 
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CKD is usually silent until its later stages, and without aggressive screening, detection may not 
occur until immediately before symptomatic kidney failure develops.
54
 At this point in the 
disease process, few opportunities exist to prevent adverse outcomes, such as further decline in 
kidney function necessitating dialysis, cardiovascular complications, shortened life span, and 
poor quality of life.  
Patients at higher risk for CKD include patients with diabetes, hypertension, or a family 
history of hypertension, diabetes or CKD itself. CKD appears more often in minority ethnic 
groups; African American, Native American, Hispanic, Asian and Pacific Islander populations 
are at higher risk of developing CKD than are white Americans. In these populations, diabetes 
and hypertension, which are predominant causes of ESRD, are more common and tend to be 
familial.
6, 55
 Patients who have a family history of those disorders or CKD are also at risk for 
developing CKD.
6
 
 
Anemia in CKD 
Anemia is the clinical manifestation of a decrease in circulating red blood cell mass and usually 
is detected by low blood hemoglobin (Hb) concentration.
56
 The normal physiological response to 
a reduction in RBCs is to increase the secretion of endogenous erythropoietin from the kidneys.
57
 
Secreted erythropoietin binds to surface receptors on red blood cell precursors in bone marrow to 
enhance differentiation and proliferation and the body responses by increasing the amount of 
hemoglobin (Hb).
56
 Therefore, due to a decline in the number of RBCs within the blood, patients 
that are diagnosed with anemia due to CKD have an impaired ability to maintain optimal levels 
of hemoglobin due to the disease‟s effect on the kidneys.56  
 13 
 
The numerous causes of anemia include blood loss, shortened red cell life span, vitamin 
deficiencies, erythropoietin deficiency, iron deficiency and inflammation.
17
 In most CKD 
patients, anemia develops due to less erythropoietin production by the impaired kidneys.
58
  
Moreover, the dialysis patients are in a state of continuous iron loss from gastrointestinal 
bleeding, blood drawing, and the dialysis treatment itself.
59
 Hemodialysis patients lose an 
average of 2 g of iron per year.
6
 Thus iron deficiency will develop in virtually all dialysis 
patients receiving erythropoietin unless supplemental iron therapy is given orally or 
intravenously.  
 
Practice guidelines 
The National Kidney Foundation-Dialysis Outcomes Quality Initiative (NKF-DOQI) 
documented clinical practice guidelines for anemia of CKD. The 2006 NKF-KDOQI clinical 
practice guidelines suggest that a CKD patient‟s hemoglobin (Hb) be checked annually 
regardless of the cause or state of their CKD.
3
 If a patient‟s Hb is < 13.5 g/dl in males and < 12 
g/dl in females, a diagnosis of anemia should be made and further evaluation is needed. Once 
diagnosed with anemia of CKD, the target range for Hb is between 11 g/dl and 12 g/dl, and 
should not go beyond 13 g/dl.
3
 Once a patient is prescribed an ESA, their Hb should be 
monitored monthly.
31
 The guidelines recommend providing iron supplementation in order to 
maintain adequate iron indices i.e. transferring saturation (TSAT) and serum ferritin levels. It is 
recommended that the patient‟s iron levels be evaluated by determining their TSAT and serum 
ferritin levels. It is also suggested that the patient‟s levels of TSAT and serum ferritin are 
monitored when ESA therapy is initiated, while increasing the dose, and when the patient is 
receiving iron supplementation.
31
 To achieve and maintain the target Hb level of 11g/dl, IV iron 
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is strongly recommended to be administered on a regular basis to most hemodialysis patients.
3
 
Iron supplementation can be oral or IV in non-dialysis and peritoneal dialysis patients. 
 
Pharmacological treatment of anemia associated with CKD   
ESAs 
Erythropoietin (EPO) is produced within the kidneys in response to a decrease in tissue 
oxygenation and regulates the production of red blood cells.
60
 The lack of EPO is a major cause 
of anemia for CKD patients.
17
 Two ESAs, recombinant epoetin alfa and darbepoetin alfa, are 
available within the United States to treat anemic CKD patients. Improved quality of life and 
symptomatic relief of anemia (fatigue, reduced exercise capacity, decreased cognition) with the 
use of ESA has been documented in clinical studies.
20, 61
 In addition to improving quality of life, 
ESAs are shown to significantly reduce the need for transfusions in patients with CKD who were 
receiving hemodialysis.
62, 63
 In a two year historical cohort study of patients undergoing 
maintenance dialysis and had targeted Hb levels of 11 to 12 g/dl, those who received ESA 
therapy lived longer than those who did not. Among those receiving an ESA, a higher dose was 
associated with lower survival.
64
  
ESAs can be beneficial in treating patients with anemia of CKD, but they have inherent 
risks. Two randomized controlled trials in patients with stage 3 and stage 4 CKD, Cardiovascular 
Risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) 
23
 and Correction of 
Hemoglobin and Outcomes in Renal Insufficiency (CHOIR), 
24
 suggest that targeting higher than 
recommended Hb levels with ESAs poses a safety risk leading to cardiovascular complications.  
 
The CREATE study was designed to investigate the effect of early anemia correction on 
cardiovascular risk in 600 predialysis patients.
23
 The primary objective of the study was to 
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determine the effect of complete versus partial correction of anemia on cardiovascular risk 
reduction; the effect of this treatment strategy on the left ventricular mass index and the 
progression of kidney disease were secondary end points. Patients with moderate anemia (Hb 
11.0- 12.5 g/dL) were randomized to receive either early or late treatment with epoetin beta. For 
the management of early treatment patients, a target Hb of 13.0 to 15.0 g/dL was used; for late-
treatment patients, 10.5 to 11.5 g/dL. By the end of the 48-month study, 127 patients assigned to 
the early-treatment group (Hb, 13.0-15.0 g/dL) had progressed to dialysis versus 111 patients 
assigned to the late-treatment group (Hb, 10.5-11.5 g/dL) (p=0.03). The study also found a 
higher risk of cardiovascular events in the early-treatment group (58 events with early treatment 
versus 47 with late treatment), but the difference was not statistically significant. Quality of life 
was the only end point that was significantly better in the high-target treatment arm. 
The CHOIR study, an open-label, prospective, randomized trial, evaluated the effect of 
correcting Hb to a target of 13.5 g/dL (n=715) or a target of 11.3 g/dL (n=717) in patients with 
CKD who were not yet receiving dialysis.
24
 The primary end point of the study was a composite 
of death, myocardial infarction, congestive heart failure, hospitalization, and stroke. A total of 
125 end-point events occurred in the high-Hb group (target Hb, 13.5 g/dL) versus 97 events in 
the low-Hb group (p=0.03) before the early termination of the trial. Quality of life was also 
measured during the study; however, no significant differences were observed between the 
groups with any of the measures used.  
Increased risk of other adverse events has been reported with the use of ESAs. Evidence 
suggests that the presence of clinically evident cardiac disease (congestive heart failure or 
ischemic heart disease) in ESA-treated patients increased their risk of mortality and of nonfatal 
myocardial infarctions, vascular access thromboses, and other thrombotic events when epoetin 
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alfa was dosed to a target hematocrit of 42%.
21, 65, 66
 Consequently, extreme caution should be 
used when exceeding the recommended Hb levels in patients with established heart disease. 
In March 2007, the Food and Drug Administration (FDA) issued a “black box” warning 
for ESAs based on its evaluation of the CHOIR and CREATE studies, as well as on the results of 
trials in patients with cancer whose outcomes were worse when treated with ESAs to higher Hb 
levels.
27
 The FDA warning advised physicians as follows: (1) use the lowest dose of ESA 
possible to gradually raise the Hb concentration and avoid the need for transfusion; (2) monitor 
Hb levels twice a week for 2 to 6 weeks after any dosage adjustment to ensure that Hb levels do 
not exceed 12 g/dL; and (3) withhold the dose of ESA if the Hb level exceeds 12 g/dL or 
increases by 1 g/dL in any 2-week period.  
Hypertension associated with the use of ESAs is considered a major adverse effect of 
therapy. In clinical trials, the onset of treatment-related hypertension occurred in the first 90 days 
of therapy, was more common in patients receiving hemodialysis, and was associated with a 
more rapid increase in hematocrit.
65, 66
 In rare cases, hypertensive encephalopathy and seizures 
have occurred. Pure red cell aplasia, a serious but very rare complication of ESA use, has been 
reported,
26
 primarily with subcutaneous administration.  
Of further concern are the recent announcements by the FDA about stating that all ESAs 
prescribed must be part of REMS to ensure the safe use of these drugs.
28
 More specifically, the 
FDA stated the program should provide patients with material and guidance to understand the 
risks associated with the use of ESAs. REMS inform healthcare professionals and patients about 
the risks associated with a medication. For medications with significant safety concerns, such as 
ESAs, REMS involve increased surveillance and/or performance/safety assessment programs. 
Healthcare professionals prescribing ESAs for anemia in patients without cancer are required to 
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provide a copy of a medication guide to each patient or their representative when an ESA is 
dispensed.
28
  
Besides the clinical issues, there are several economic challenges associated with the use 
of ESAs. Reimbursement policies for the coverage of ESAs vary by patient type and insurance 
coverage. Most patients with CKD who require dialysis receive Medicare, which covers ESA 
therapy. Medicare Part B covers ESAs for eligible patients but only when doses are administered 
in the physician‟s office or clinic, making it difficult for patients who choose to self-administer 
to receive coverage. Patients who are not undergoing dialysis and those who are not eligible for 
Medicare may use private insurance for ESA coverage. Erythropoiesis-stimulating agents are 
considered specialty items and usually have the highest copay allocation (Tier 4), may require 
prior authorization, and may have quantity limits in place.  
 
Iron supplementation 
Iron supplementation in CKD-related anemia can be administered either orally or intravenously 
(IV). Based on the 2005 U.S. Renal Data System Annual Report, approximately 70% of 
hemodialysis patients in the United States receive parenteral iron.
67
 Although oral iron is less 
expensive and easier to administer, IV iron enables the administration of larger doses of iron and 
may be better tolerated by patients.
68
 The main adverse reactions to oral iron are gastrointestinal, 
such as nausea, abdominal pain and bloating, darkening of the stools, constipation, diarrhea and 
vomiting. Such gastrointestinal side effects may limit adherence and dose.
69
 To overcome these 
problems, intravenous iron preparations, such as iron dextran, sodium ferric gluconate and iron 
sucrose, have been used for iron replacement. Meta-analysis of studies evaluating the use of IV 
iron compared to oral or no iron show that in general IV iron therapy seems to be no more 
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efficacious than oral or no iron in increasing Hb or Hct within 2 months from the start of the 
treatment.
70
 However, when nondextran iron (i.e. iron sucrose and sodium ferric gluconate) is 
considered, IV iron was found to be more efficacious than oral or no iron in increasing short term 
Hb or Hct levels. Results also showed that IV iron caused more drug intolerance, but it is still not 
clear if it causes more serious adverse events compared to oral iron.
70
 Another meta-analysis of 
randomized clinical trials assessing IV iron versus oral iron supplementation shows that in 
hemodialysis patients IV iron was more efficacious in improving Hb levels as compared with 
oral iron regardless of ESA use and type of IV iron preparation used.
71
 In non-dialysis anemic 
CKD patients, the overall benefit of IV iron compared to oral iron was of a small magnitude and 
its clinical significance was not clear.  Furthermore, ESA dose was significantly decreased by the 
use of IV iron compared with oral iron.
71
 
Iron dextran has been associated with several adverse events, anaphylactoid reactions 
being most common.
72-74
 Hypersensitivity reactions that are considered serious and life-
threatening along with the occurrence of delayed reactions such as arthralgia, myalgia, fever and 
malaise have been associated with the use of IV iron dextran.
75, 76
 Relative to low molecular 
weight dextran, total and life-threatening adverse drug reactions were significantly more frequent 
among recipients of high molecular weight iron dextran and significantly less frequent among 
recipients of sodium ferric gluconate and iron sucrose.
77
 Sodium ferric gluconate and iron 
sucrose have a much lower rate of serious adverse events.
74
 Iron sucrose and sodium ferric 
gluconate have been proven to be safe for use in „iron-dextran sensitive‟ population.72, 78, 79 Iron 
may also have other important toxic effects.
74
 Excessive use of iron could theoretically increase 
the risk of sepsis and infection-related mortality,
80, 81
 worsen atherogenesis,
82
 and increase the 
risk of cardiovascular disease events.
74, 82
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Several randomized clinical trials have established the safety and efficacy of IV iron 
preparations in anemic CKD patients. The Dialysis Patients Response to IV Iron with Elevated 
Ferritin (DRIVE) study demonstrated the efficacy of intravenous ferric gluconate to improve 
hemoglobin levels in anemic hemodialysis patients who were receiving adequate epoetin doses 
and who had high serum ferritin and low transferrin saturation.
48
 IV iron resulted in a greater 
increase Hb levels in the IV iron group (1.6 ± 1.3 g/dl vs 1.1 ± 1.4 g/dl, p = 0.028) than in the 
control group.
48
 Hemoglobin response occurred faster (p = 0.035) and more patients responded 
after IV iron than in the control group (p = 0.041). 
48
 As a follow up, DRIVE-II study reported a 
6 week observational extension designed to investigate how ferric gluconate impacted epoetin 
dosage after DRIVE. The study concluded that patients in the IV iron group required 
significantly less epoetin dose than their DRIVE dose (mean change of -7527 ± 18,021 IU/wk, p 
= 0.003).
49
 Over the entire study period (DRIVE and DRIVE-II), the control group experienced 
significantly more serious adverse events than the IV iron group (incidence ratio = 1.73, p = 
0.041).
48, 49
 Nissenson et al. showed in their multi-center, randomized clinical study that 
hemodialysis patients with serum ferritin below 100 ng/ml or transferring saturations below 18% 
need supplementation with IV iron in excess of 1 gm to achieve optimal response in hemoglobin 
and hematocrit levels, and confirm the National Kidney Foundation Dialysis Outcomes Quality 
Initiative (NFK-DOQI) guidelines regarding IV iron supplementation.
53
 A randomized, 
controlled, parallel-group trial comparing iron sucrose and sodium ferric gluconate found both 
drugs to be equally effective in maintaining hemoglobin levels, and equally well tolerated in a 
stable ESA treated hemodialysis population.  
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Economic background 
Admission to a hospital is a frequent event among chronic kidney disease patients, occurring in 
almost 50% of ESRD patients each year, compared with 22% in the general Medicare 
population.
83
 Hospitalization accounts for a large fraction of the cost of care in the CKD 
population, followed by dialysis and non-dialysis physician and supplier costs.
5
 Understanding 
the terminology of costs, charges and reimbursements from a hospital‟s perspective are 
important. From a hospital‟s perspective, costs refer to the price a hospital pays for the resources 
it consumes. This is different than a charge, which is simply a list price. 
35
 Charges will always 
be higher than the actual hospital costs, hence patients who can pay will cover the losses from 
those who cannot afford to pay.
35
 
Charges are known to inflate the economic burden of hospitalization, hence cost-to-
charge ratios are used to better approximate actual cost from charges.
84, 85
 For each patient 
discharge at a teaching hospital, a charge for the various service categories is reported to the 
University HealthSystem Consortium (UHC) database. Two corrections are applied to each of 
these service category charges.
86
 The first correction is to multiply the service category charge 
by the ratio of cost to charge (RCC). This factor is derived for each cost center for each hospital, 
on the basis of annual reports to Health Care Financing Administration, by dividing the total 
costs by the total charges for each cost center. The RCCs vary from hospital to hospital and are 
also analyzed to estimate percentiles for trimming the data to eliminate outliers. The second 
correction is that UHC applies a labor adjustment to take into account differences in geographic 
wage indices. After these two corrections are made, the resultant cost values for each patient 
discharge are entered into the database. The use of the RCC has shown a correlation with internal 
accounting costs at a level above 0.90.
84
 While this method does not report absolute costs, the 
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calculation provides data that have internal consistency within each institution, and that makes it 
possible to compare the costs of one disease with those of another, as well as to compare the 
costs for the same disease (DRG) at different institutions. The accuracy of the derived costs is to 
a large extent governed by the accuracy of the data submitted by each institution. 
In the United States, the government is the major payer of hospital services through 
Medicare and Medicaid.  In 1982, Medicare adopted a prospective payment system (PPS) for 
hospital reimbursement to control costs by capping the allowable reimbursement.
87
 The PPS 
works by dividing admissions into diagnosis-related group (DRG) categories. A DRG is 
computed by taking into consideration the affected organ system, up to nine ICD-9-CM 
diagnosis codes, up to 6 ICD-9-CM procedure codes and morbidity and gender.
87
 Hospitals are 
then reimbursed a fixed rate depending on the DRG.  Each DRG has an associated DRG weight 
that reflects the average level of resources a Medicare patient in a particular DRG will utilize. 
The DRG weight can range from greater than 0 to less than 20.  An average hospital stay would 
have a DRG weight of 1. Conditions with greater costs are assigned a higher DRG weight.  
Hospitals are then reimbursed a fixed rate depending on the relative weight of the DRG. Besides 
this, reimbursements are also adjusted for geographic differences in wage, hospital teaching 
status, proportion of low income individuals a hospital treats and cost outliers.   
 
Confounding factors 
 
Assessing economic impact of drug utilization can be complicated by variations in population 
demographics, the heterogeneity of physician prescribing habits, variations in institutional drug 
use formulary controls across different hospital settings, and the clinical condition of the patient. 
There is empirical evidence in the literature suggesting stage of kidney disease, white race, 
female gender, older age (>74 years), referral to a nephrologist, presence of cardiovascular 
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disease, diabetes, dyspnea, psychiatric disorders, gastrointestinal bleeding in previous year and 
patient laboratory measures (Hb, serum ferritin, TSAT levels) to be important predictors of ESA 
and IV iron use in anemic CKD patients. 
7, 38, 39
 This study will examine five main domains for 
predicting IV iron utilization, consisting of patient characteristics, clinical conditions, physician 
characteristics, hospital characteristics and treatment characteristics. 
Any epidemiologic investigation attempting to describe the relationship between 
exposure and outcome must consider potential confounders.
88
 Confounding factors are variables 
that are associated with the outcome as well as the exposure, and they pose a serious threat to the 
accurate interpretation of study results.
89
  To explain the phenomenon of confounding, it is 
necessary to consider the relationship between an exposure and the occurrence of a disease state 
(refer Figure 1). In order for a variable to be a potential confounder, it needs to have the 
following three properties: 1) the variable must have an association with the disease, that is, it 
should be a risk factor for the disease; 2) it must be associated with the exposure, that is, it must 
be unequally distributed between the exposed and unexposed groups; and 3) it must not be an 
effect of the exposure, nor be a factor in the causal pathway of the disease.
89
  In the presence of 
confounders, an association may appear to be present when one does not exist or there may seem 
to be no association when a true association does exist.
89
 Confounders should be identified from 
the base population, not the study sample, preferably a priori based on previous investigations or 
expert opinion.
36, 37
 Since almost all investigations examine a small subset of a larger population, 
it is possible that a confounding effect within the population may not be present within the 
sample. Known confounders should be included regardless of their “statistical significance” in 
the sample.  
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Figure 2.1: Properties of a confounder 
 
 
 
 
 
 
 
Once confounders are identified they must be controlled. They can be controlled through 
restriction, matching, randomization in the design phase, and stratification and multivariate 
analysis in the analytic phase.
36, 37
 Random allocation of exposure should equalize the 
distribution of all potential confounders, even unknown ones, across different levels of drug 
exposure. Randomization is aimed at making the two groups perfectly similar apart from the 
independent intervention variable under assessment as exposure. However, this method is 
appropriate only in prospective, experimental study designs and the retrospective nature of 
database analyses does not allow the use for this technique. Retrospective database investigations 
more commonly use matching and restriction. Matching is a way to control for confounding 
where two compared groups are made “similar” with regard to the distribution of selected known 
extraneous factors. In practice, matching maybe difficult, especially when there are several 
factors to match for. In case-control studies matching may also lead to “overmatching”. 
Restriction limits scope of design to only one level of confounding factor (e.g. age category 18-
24 years), which is the simplest way of dealing with confounding, but may limit the 
generalizability of the investigation.
90
  
Association Risk factor 
Relationship of interest 
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Disease Exposure 
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Stratification or multivariate analysis/modeling can be used to control for confounding at 
the analysis phase. Stratification quantifies the relationship between exposure and outcome as a 
pooled estimate with respect to the confounder. It is performed in two stages: the first stage 
requires computation of a stratum-specific rate ratio for each level of the stratifying 
(confounding) variable.
90
 The second stage involves pooling the results into a single estimate that 
represents the overall effect of the exposure, adjusted for the effect of the confounding factor.
90
 
Multivariate modeling helps determine the relationship between risk factors and outcomes, 
allowing assessment of many factors simultaneously. 
Several variables have been acknowledged as potential confounders in the relationship 
between drug use and total costs in anemia in chronic kidney disease. Specifically, patient 
demographics (age, race, sex), underlying severity of illness, dialysis status, drug insurance 
coverage type, physician specialty, mortality and comorbid conditions, have been identified. 
7, 11, 
38-43
 Differences in mortality are especially important in drug utilization and cost studies since 
patients who die during their hospitalization have truncated costs and curbed utilization. The risk 
of death due to comorbid conditions has been estimated using the Stoke Cormobidity Grade 
(SCG), 
91
 the Khan index, 
92
 the Davies index, 
93
 and the Charlson comorbidity index.
94
 DRG 
categories have been used as a surrogate for underlying severity of illness.
95
  
There is currently no well-validated severity of illness score for CKD. Other 
investigations have used a variety of techniques including the Stoke Cormobidity Grade (SCG),
91
 
the Khan index,
92
 the Davies index 
93
 and the Charlson comorbidity index.
94
 Unlike other 
indices, the Davies index does not include age, because it was specifically designed to be used in 
conjunction with age as an independent covariate. Other comorbidity indices that are in use in 
studies on ESRD patients assign different weights to different comorbidities, such as the Khan or 
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the Charlson index, with the weights based on the impact of comorbid diseases on survival.
96
 
However, the impact of comorbid diseases on survival may be rather different from their impact 
on health status and resource use. 
96
 The All Patient Refined Diagnosis Related Groups (APR-
DRG) classification system is used to adjust for severity of underlying illness.
97
 The APR-DRG 
system is an enhancement of the DRG structure and is considered a good predictor of hospital 
costs and resource use.
98, 99
     
Hospital level factors can also confound the relationship between drug utilization and 
total cost. As previously mentioned, DRG payments are calculated by adjusting for hospital 
specific factors. Hospital bed size, geographical region of the hospital are also confounders to be 
considered. These factors are confounders since they directly impact hospital costs and drug 
utilization can vary depending on anemia management policy of different hospitals. 
 
Previous investigations 
Economic burden of CKD  
Several economic studies have been conducted to examine the resource use and costs associated 
with CKD. Robbins et al. conducted a retrospective claims analysis of a nationwide managed 
care medical and pharmacy database from 1998 to 2001.
100
 The main outcome measures were 
total healthcare charges, primary diagnoses and diagnosis-related groups (DRGs). The per-
patient-per-month charges were $4,265 in the pre-dialysis period, $35,292 in the dialysis period, 
and $15,399 in the post-dialysis period.
100
 The most common primary diagnosis categories 
during all time periods were chronic renal failure and congestive heart failure. Hence CKD 
patients generated significant charges to the health plan both before and after dialysis. Submitted 
charges were used in this analysis, and not allowed charges, which may result into overstating 
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the actual financial burden for the managed care plan. Claims for medications were measured; 
however, this study did not assess the impact of medications on patient outcomes such as 
mortality, hospitalizations or hospital length of stay.  
Another retrospective study evaluated medical and pharmacy claims for 1,936 incident 
dialysis patients from 22 states in the 12-month period preceding initiation of dialysis.
101
 Of 
these, 48.7% did not have any interventions associated with optimal care for CKD. Only a 
minority of patients received prescription iron preparations (6.8%), ESA therapy (10.5%), yet 
more than 40% were diagnosed with anemia. Of the ESA users, 72.4% were also receiving other 
interventions (such as vascular access placement) to appropriately manage anemia of CKD. 
Estimated mean charges per patient over the study period of $26,204, $9,623, and $1,505 for 
facility services, professional services and outpatient pharmacy respectively were reported.
101
 
Estimated charges reported in this analysis were calculated from a Medicare-based fee schedule.  
St. Peter et al. conducted a retrospective cohort study of 1995 through 1998 incident 
dialysis patients to study the distribution of costs during the 24 months prior to initiation of 
dialysis. Patient data were obtained from Centers for Medicare and Medicaid Services (CMS). 
Costs sharply increased in the last six months prior to initiation of dialysis. Hospitalization was 
the major component of cost throughout the study period. Patients who initiated hemodialysis 
incurred a higher cost compared to patients who initiated other modes of kidney replacement 
therapy. Increased comorbidity burden, such as presence of diabetes and cardiovascular disease 
was associated with higher cost.
41
 The inclusion criteria limited entry to patients aged ≥ 67 years, 
hence limiting generalizability of the results mainly to the Medicare population with CKD.  
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The studies discussed so far mainly focused on the increasing economic burden of CKD 
and suggested that a focus on timely management of CKD may prevent future morbidity and 
resultant resource use and costs. The following section discusses studies examining the economic 
burden of anemia in CKD. 
Economic burden of Anemia 
The presence of anemia may be a significant contributor to health-related costs among patients 
with CKD. Wish et al. conducted a retrospective claims database analysis to examine the 
association of anemia and anemia management with healthcare expenditure and utilization in 
CKD patients before onset of dialysis.
102
 Of the 37,105 CKD patients, 9,807 (26%) had anemia; 
59% of these received some form of anemia treatment, with 48% receiving ESA therapy. The 
total adjusted per patient per month healthcare expenditure for all CKD patients was estimated to 
be $2,749.
102
 Patients with anemia had significantly higher overall expenditure, which was 52% 
higher than those without anemia ($4,076 vs. $2,664; P < 0.0001). Total expenditure was 17% 
higher for untreated versus treated anemic patients, largely due to higher inpatient expenditure in 
the untreated cohort ($4,470 vs. $3,806; P < 0.0001).
102
  
Two other studies examined the economic burden of anemia in selected disease states.
29, 
40
 Ershler et al. conducted a cross-sectional comparison of direct and indirect costs between 
anemic and non-anemic populations in six chronic disease conditions (rheumatoid arthritis, 
inflammatory bowel disease, cancer, chronic kidney disease, chronic obstructive pulmonary 
disease, and chronic heart failure) in the time period of 1991 to 2001. The CKD population had 
the highest prevalence of anemia, and the CKD anemic patients incurred the greatest average 
annual direct costs ($78,209).
40
 After adjusting for baseline characteristics including severity, the 
 28 
 
difference in direct costs between anemic and non-anemic patients for the CKD group was 
$20,529.
40
 Nissenson et al estimated an average annualized healthcare payment per patient 
difference as $28,757 between anemic and non-anemic patients in the CKD population ($41,292 
versus $12,535; P <0.0001).29 Overall, medical costs for anemic patients were twice as much for 
non-anemic patients with the same comorbid conditions.29, 40  
Utilization of IV iron and ESA 
The goal of anemia management in patients on hemodialysis is to use a low ESA dose in 
conjunction with IV iron therapy to achieve and maintain appropriate Hb levels. Taylor et al. 
showed that the regular IV iron supplementation in hemodialysis patients improved the response 
to ESA therapy in terms of serum ferritin and Hb levels.
103
 This was a single center study 
studying 46 hemodialysis patients receiving ESA therapy. At the end of the 6-month study 
period, the patients receiving IV iron supplementation showed significant increments in Hb and 
serum ferritin levels, and significant reductions in epoetin dose.
103
 The DRIVE-II study reported 
a 6-week observational extension designed to investigate how ferric gluconate impacted epoetin 
dosage after DRIVE.
49
 By the end of the observation, patients in the ferric gluconate group 
required significantly less epoetin than their DRIVE dose (mean change of -7527 ± 18,021 
IU/week, P = 0.003), whereas the epoetin dose essentially did not change for patients in the 
control group (mean change 649 ± 19,987 IU/week, P = 0.809). A prospective multi-centre 
clinical trial in iron-replete hemodialysis patients found a regular 50 mg weekly dosing schedule 
of IV iron sucrose to maintain stable iron stores and Hb levels, and allowed considerable dose 
reductions of ESA therapy.
104
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The proposed investigation will be the first to study anemia management in CKD patients 
and its impact on total hospital costs and LOS, using data from multiple academic hospitals. A 
couple of single center reports have been published studying utilization of IV iron and its impact 
on costs.
50, 51
 These investigations agree that use of IV iron along with ESA have near optimal 
outcomes in anemic patients with chronic kidney disease and lead to lower costs. Sepandj et al. 
conducted a prospective study with economic analysis comparing use of IV iron and oral iron in 
a group of 50 hemodialysis patients on epoetin therapy. More than half of the patients were 
unable to maintain adequate iron stores and experienced severe gastrointestinal intolerance in the 
oral supplementation group. Use of IV iron led to an annual cost reduction of $3,016 Canadian 
dollars in chronic dialysis patients (n = 50).
50
 The study concluded IV iron regimen is a safe, 
effective and economically favorable means of iron supplementation in a subset of hemodialysis 
patients in whom oral iron supplementation has failed. Bhandari et al. evaluated the economic 
benefit of IV iron in a prospective non-blinded study of 22 hemodialysis patients. Patients were 
established on subcutaneous epoetin and given IV iron over seven consecutive dialysis sessions 
and supplemental monthly doses with regular monitoring for four months. Use of IV iron led to 
reduced requirements of ESA (4000 units/week vs 2000 units/week; P = 0.03), and hence 
resulted in cost-savings of £21/week.
51
  
There is a dearth of research done studying the utilization of IV iron in anemic CKD 
patients. A single previous investigation reported the trends in IV iron use among US Medicare 
dialysis patients.
46
 The study reported a consistent increase in the use of IV iron in ESRD 
patients from 1997 to 2002 across all age, sex, race, and primary ESRD diagnosis categories. 
Ferric gluconate and iron sucrose were reported as the predominant form of therapy in this 
population. Intravenous iron therapy was used in a much smaller percentage of peritoneal 
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dialysis patients compared to hemodialysis patients, and racial and geographical variability were 
observed in overall IV iron usage in the United States.
46
 However, the study did not evaluate the 
economic impact of IV iron utilization.  
There have been several studies investigating the utilization of ESAs in CKD patients and 
its impact on healthcare utilization and costs.
42,43,105
 Powe et al conducted a longitudinal, 
matched cohort study using Medicare claims data to examine the effects of ESA therapy on 
hospital admission, readmissions, length of stay (LOS) and hospital costs.
43
 Dialysis patients 
who received ESA were matched with controls on age, sex, race, cause of ESRD and dialysis 
modality. The results suggested that anemic dialysis patients treated with ESA during the study 
period had a slightly increased (8%) probability of being admitted to the hospital. However, 
among those patients admitted, treatment with ESA appeared to decrease the number of 
readmissions, resulting in a net decrease in overall hospital admissions (176 vs 138 admissions 
per 1000 patients, P = 0.029). The study also suggested that treatment with ESA decreased both 
the number of days that dialysis patients spent in the hospital (2911 vs 1602 days per 1000 
patients, P = 0.0001) and the cost to hospitals ($2695 vs $2324 per 1000 patients, P = 0.03) for 
the care of these patients.
43
 Maddux et al conducted a retrospective claims analysis using a large 
U.S. health plan database to compare clinical outcomes, healthcare utilization, and costs of care 
in anemic patients with CKD not on dialysis receiving or not receiving ESAs.
42
 ESA recipients 
had lower total monthly healthcare costs than did untreated anemic patients ($3876 vs $4758; p = 
0.0061). Lower monthly inpatient and emergency department costs in treated versus untreated 
anemic patients ($2507 vs 3849 and $46.56 vs $81, respectively; both p < 0.0001) outweighed 
higher outpatient and laboratory costs from ESA use ($602 vs $397 and $23.50 vs $14.34, 
respectively; both p < 0.0001) multivariate analyses revealed that ESA users had lower adjusted 
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monthly total costs ($2962 vs $3373) compared with non-ESA patients. ESA use was associated 
with mean total cost savings of $411 per patient per month, reflecting reduced inpatient and 
emergency department visits and costs.  Moyneur et al. quantified the economic impact of pre-
dialysis epoetin on healthcare and work loss costs in CKD, with a focus on employer‟s 
perspective.
106
 Using employer claims data from January 1998 to January 2005, direct and 
indirect costs were compared between CKD-anemic patients treated with ESA before dialysis 
and those not treated with an ESA. Anemic CKD patients treated with ESA before dialysis had 
significantly lower direct and indirect costs compared to non-ESA treated patients Incremental 
direct and indirect cost savings for ESA treated patients were $1443 and $328 per member per 
month (PMPM) (p < 0.0001), respectively compared to non-ESA treated patients with anemia. 
After multivariate adjustment, direct and indirect costs remained significantly lower by $852 and 
$308 PMPM (p < 0.001), respectively for the ESA-treated group.
106
  
From an economic perspective, Pizzi et al demonstrated that the administration of IV iron 
in conjunction with ESA is more cost-effective as compared to ESA therapy alone in anemic 
dialysis patients.
47
 A cost-effectiveness model was developed, consistent with the DRIVE 
studies, using decision analysis with a 12-week time horizon. The primary effectiveness measure 
was the mean hemoglobin increase in the intent to treat patient groups comparing ESA with or 
without sodium ferric gluconate. Costs were computed using projected 2007 US Medicare 
reimbursements for the treatments and for serious adverse events, with effectiveness factored by 
the increase in hemoglobin. Use of IV iron represented a net-savings of $1,390 per g/100 ml 
increase in Hb over a 12 week period.
47
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In summary, there has been no investigation looking at long term utilization of IV iron 
and ESA in anemic CKD patients, and evaluating the resultant economic impact on hospital LOS 
and costs. CKD of anemia has a high economic burden in terms of resource use and costs. 
Several single center investigations have suggested economic benefit with the use of IV iron 
supplementation in hemodialysis patients on ESA therapy. Use of IV iron along with ESA has 
been shown to be a cost-effective option as compared to using ESA alone. Also, it is established 
that use of ESA therapy is associated with better outcomes, shorter LOS and lower hospital 
costs. The recent NKF-KDOQI guidelines recommend the use of iron supplementation in all 
anemic CKD patients on ESA therapy. To achieve and maintain the target hemoglobin (Hb) level 
of 11g/dl, IV iron is strongly recommended to be administered on a regular basis to most 
hemodialysis patients.
3
 Iron supplementation can be oral or IV in non-dialysis and peritoneal 
dialysis patients. 
Clinical trials have established the safety and efficacy of IV iron supplementation in 
anemic CKD patients already on ESA therapy. However, long term utilization of IV iron remains 
untested by clinical trials. A large multi-center investigation may help to quantify the economic 
impact of IV iron utilization in anemic chronic kidney disease patients. Interesting utilization 
patterns of IV iron and ESA therapies in multiple hospitals across the nation will provide a 
relatively clear picture of the medication profile and resulting economic impact in anemic CKD 
patients. The proposed investigation should have greater external validity than previous studies.  
Data from forty teaching hospitals will be considered making it a large multi-center 
investigation. A multi-center investigation will provide a larger sample size than previous single 
center reports.  
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Statement of research hypotheses 
 
As a result of the review of the CKD literature and information regarding utilization of IV iron 
and ESA, the following hypotheses were postulated and tested in this inquiry. 
Research question 1: 
Utilization and days of therapy for IV iron and ESA therapy 
H0-1a: There is no significant change in the utilization of IV iron and ESA over time. 
H0-1b: There are no significant difference in the utilization of IV iron and ESA, compared to 
ESA-therapy alone over time. 
 
Research question 2: 
Predictors of IV iron and ESA use 
Patient characteristics 
H0-2a: There exists no significant association between patient age and IV iron and ESA use 
relative to ESA use alone.  
 
H0-2b: There exists no significant association between patient race and IV iron and ESA use 
relative to ESA use alone.  
 
H0-2c: There exists no significant association between patient gender and IV iron and ESA use 
relative to ESA use alone.  
 
H0-2d: There exists no significant association between patients‟ length of hospital stay and IV iron 
and ESA use relative to ESA use alone.  
 
H0-2e: There exists no significant association between patients‟ source of payment and IV iron 
and ESA use relative to ESA use alone.  
 
 
Patient clinical condition 
 
H0-3a: There exists no significant association between patients‟ admission status and IV iron and 
ESA use relative to ESA use alone.  
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H0-3b: There exists no significant association between patient severity of illness and IV iron and 
ESA use relative to ESA use alone.  
 
H0-3c: There exists no significant association between patient dialysis status and IV iron and ESA 
use relative to ESA use alone.  
 
H0-3d: There exists no significant association between patient discharge status and IV iron and 
ESA use relative to ESA use alone.  
 
 
Physician characteristics 
 
H0-4: There exists no significant association between physician specialty and IV iron and ESA 
use relative to ESA use alone.  
 
 
Hospital characteristics 
 
H0-5a: There exists no significant association between total hospital costs and IV iron and ESA 
use relative to ESA use alone.  
 
 
Research question 3: 
Impact of IV iron use on hospital LOS 
 
H0-6: Given other things constant, patients with anemia of CKD on ESA therapy alone incur 
greater LOS compared to patients on IV iron +ESA therapy. 
 
 
Research question 4: 
Impact of IV iron use on total hospital costs 
 
H0-7: Given other things constant, patients with anemia of CKD on ESA therapy alone incur 
greater total hospital costs compared to patients on IV iron +ESA therapy. 
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CHAPTER 3 
 
Methodology 
 
 
Data 
 
The data for this research comes from University HealthSystem Consortium (UHC) hospital 
database. The UHC is a member-driven alliance of approximately 90% of the nonprofit academic 
medical centers in the United States. Table 3.1 describes organizational characteristics such as 
bed size and geographical region of the teaching hospitals within the UHC database. The 
hospitals in the UHC database were compared with the latest American Hospital Association 
(AHA) statistics to assess their national representation. The AHA is the national organization 
that represents and serves all types of hospitals, health care networks, patients and communities. 
It contains information on more than 5,000 hospitals, health care systems and other providers of 
care and over 37,000 individual members.
107,108
 According to the National Center for Health 
Statistics, the AHA is considered a national standard for comparing U.S. hospitals and their 
characteristics.
109
 In comparison with the national statistics, small bed-sized hospitals were 
under-represented in the database. The database contained more hospitals from the north-east 
and south-east region than the national average. Overall, the sample from the UHC database 
appeared to be an adequate national representation of hospitals listed in the AHA database.  
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Table 3.1: Representation of hospitals in the UHC database 
Variables UHC data (%) National AHA Statistic (%) 
Bed size 
1-199 
200-299 
300-399 
400-499 
500 or more 
 
0.05 
3.47 
14.02 
10.39 
72.07 
 
74 
11.21 
6.40 
3.26 
5.06 
Geographical region 
Northeast 
Southeast 
Southwest 
Midwest 
West 
 
22.57 
22.08 
13.52 
23.75 
18.08 
 
13.98 
15.33 
29.58 
22.91 
18.20 
   
 
For this study, UHC‟s Clinical Resource Manager (CRM) Data Base was used. This 
electronic repository combines administrative, clinical, and financial data from participating 
UHC member institutions. Data are gathered from hospital discharge summaries and Uniform 
Billing-92 data. Patient records contain detailed information on inpatient care, and this includes: 
primary and secondary diagnoses (in International Classification of Diseases, 9th Revision, 
Clinical Modification [ICD-9-CM] format), inpatient procedure codes (in ICD-9-CM format), 
patient demographic information (age, race, gender, primary and secondary insurer), and hospital 
demographic information (bed size and geographical location). The database also contains 
admission and discharge dates as well as information on comorbidities, severity of illness, 
physician specialty, length of stay (LOS), costs, and clinical outcomes such as inpatient mortality 
and complications rates. Cost estimates of inpatient care are available for every discharge, and 
this information can be aggregated on multiple levels, including diagnosis-related groups 
(DRGs). For each hospital, the total costs have been broken down by component sources. The 
UHC database provides information on both the median and mean costs for any component 
service. 
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Study population 
The data warehouse was electronically queried for patients with Chronic Kidney Disease using 
ICD-9-CM codes. Eligible patients were those who were admitted to a UHC hospital with 
primary or secondary diagnoses of CKD and received either IV iron or ESA or both at least once 
during the period of January 1, 2006, and December 31, 2008.  
 
Inclusion and exclusion criteria 
Patients eligible for inclusion had to be at least 18 years of age with primary or secondary 
diagnosis of CKD. The patients in the treatment cohort were required to have received ESA or 
IV iron treatment during the study‟s time period. Patients with evidence of cancer diagnosis, 
chemotherapy or radiotherapy, blood transfusion, severe gastrointestinal bleeding, HIV/AIDS, 
during the observation period were excluded to avoid including patients receiving ESA or IV 
iron for reasons other than anemia of CKD. Diagnoses and procedure codes used for inclusion 
and exclusion are described in Tables 3.2 and 3.3.  
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Table 3.2: Diagnoses codes (ICD-9-CM) and Procedure codes used to identify Chronic Kidney 
Disease patients 
Diagnoses Codes 
Description ICD-9-CM Codes 
Chronic renal failure  
 
Renal failure, unspecified  
 
Renal sclerosis, unspecified  
 
Hypertensive renal disease   
 
Hypertensive heart and renal disease   
 
Nephrotic syndrome  
 
Chronic glomerulonephritis  
 
Nephritis (NOS as acute or chronic)  
 
Chronic pyelonephritis (without lesion of 
renal medullary necrosis)  
 
Chronic pyelonephritis (with lesion of renal 
medullary necrosis)  
 
Renal Dialysis status 
 
Fitting or adjustment to dialysis catheter 
 
Adequacy testing for hemodialysis or 
peritoneal dialysis 
 
Encounter for dialysis and dialysis catheter 
care 
 
Anemia of Chronic Kidney disease  
585.1-585.6, 585.9 
 
586 
 
587 
 
403.00-403.9 
 
404.00-404.9 
 
581.0-581.9 
 
582.0-582.9 
 
583.0-583.9 
 
590.00 
 
 
590.01 
 
 
V45.1 
 
V56.1-V56.2 
 
V56.3, V56.31, V56.32 
 
 
V56.0, V56.8 
 
 
285.21 
Procedure codes 
Description ICD-9-CM Codes 
Hemodialysis 39.95 
Peritoneal dialysis 54.98 
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Table 3.3: Diagnoses codes (ICD-9-CM) and Procedure codes used in exclusion criteria 
Diagnoses Codes 
Description ICD-9-CM Codes 
 
Neoplasms 
 
Blood Transfusion 
 
Kidney/other organ transplant 
 
Gastrointestinal bleeding 
 
HIV/AIDS 
 
140.00-239.00 
 
V58.2 
 
996.8, E878.0, V42 
 
569.3, 578.9, 626, 627 
 
042, V08, 795.71 
Procedure codes 
Description ICD-9-CM Codes 
Chemotherapy 
 
Radiation therapy 
 
Blood transfusion 
 
Kidney/organ transplant 
 
Gastrointestinal bleeding 
00.10, 99.85, 99.25, 92.28, 99.28 
 
14.26, 92.41, 92.25, 92.21, 92.22, 0.18, 14.27, 92.26 
 
99.03, 38.92, 38.94, 99.02 
 
00.91-00.93 
 
44.43, 44.44 
  
 
 
Study Design 
This was a retrospective cohort analysis of patients within the University Health System 
Consortium database.  The exposure of interest was IV iron and ESA therapy, and the outcome 
was the difference in total hospital costs and length of stay between patients only on ESA, and 
those on ESA and IV iron. Only incident users of IV iron and ESA were included in the study.  
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Data Collection 
The UHC data warehouse was electronically queried for CKD patients who have received at 
least one dose of IV iron and ESA (epoetin or darbepoetin) or both, using the UHC Generic Drug 
codes. Data elements important from a hospital perspective were collected.  This includes: age, 
insurer, gender, race, admission source, primary and secondary diagnosis, additional ICD-9 
codes (e.g. underlying medical condition), physician specialty, discharge severity of illness 
codes, total LOS, dates of admission and discharge, DRG weight, procedure codes, hospital bed 
size, geographical region, dose, frequency and type of IV iron and ESA prescribed.  
The subject information was received in four main SAS datasets from UHC. The master 
dataset was built by integrating the information using the selection criteria shown in Figure 3.1 
below. The first dataset contained information on 210,296 patient records from UHC hospitals 
who received either ESA or IV iron at least once during the 30 month study period from January 
2006 to December 2008. This dataset also contained primary diagnoses codes, primary procedure 
codes, primary and secondary payer codes, admission and discharge dates, admission and 
discharge status, severity of illness and risk of mortality codes, ICU days, LOS and total hospital 
costs for each patient record. There was complete information on hospital location by state and 
hospital bed size for hospitals. The second dataset contained complete secondary diagnoses 
information for 210,296 patients. The third dataset contained information on comorbidities for 
206,680 patients. The fourth dataset contained complete information on the number of units and 
charges for each drug administered for 94,668 patients. The information from these four datasets 
was merged to create the master dataset. The patient files that contained the primary and 
secondary diagnoses codes were matched from both the first and second datasets and only those 
patient files containing both primary and secondary diagnoses codes of CKD were included in 
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the master dataset. On merging patient information from the two datasets, duplicate patient 
identifiers were identified. Only those patient records with unique patient identifiers (N=84,447) 
were retained in the master dataset.  
After creating the master dataset, a few variables had missing values (refer Table 3.4). 
Considering the small proportion of missing values, for the categorical independent variables, a 
separate category of „Unknown/Other‟ was created for all the missing values. Patients with 
missing values for hospital costs were dropped from further analyses.  
Figure 3.1: Data integration steps to determine subject selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dataset 3 
In-patients using IV or 
ESA with information on 
comorbidities (N = 
206,680) 
Dataset 4 
Information on drug use, 
charges, units and date of 
charge (N = 94,668) 
Dataset 1 
In-patients using IV or ESA 
with primary diagnoses, 
procedures, admission and 
discharge codes, SOI, LOS, 
total hospital costs, hospital 
information listed 
(N = 210,296)  
Dataset 2 
In-patients using IV or 
ESA with secondary 
diagnoses listed (N = 
210,296) 
Master Dataset 
In-patients using IV iron or ESA with 
complete information on outcome and 
independent variables (N = 84,447) 
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Table 3.4: Variables with missing values 
Independent variables 
Variable name Missing values (%) 
Admission Status 
 
Physician specialty 
 
Bed size 
 
Geographical region (hospital) 
 
811 (0.9%) 
 
3984 (4.5%) 
 
112 (0.12%) 
 
903 (1.03%) 
 
Outcome variables 
Variable name Missing values (%) 
Total hospital costs 1118 (1.28%) 
 
 
 
Outcomes 
There were two outcomes of interest in this analysis. First, the total hospital length of stay and 
ICU length of stay were evaluated in number of days. Second, total costs in US dollars were 
assessed. Costs were adjusted for inflation using the 2008 Consumer Price Index for hospitals.
110
 
When comparing economic values over multiple years, it is crucial to adjust for the time value of 
money. The consumer price index (CPI) measures the average change in inflation over time of 
goods and services. The reference index for the CPI is set at 100 which represents the average 
price level for the 36 month period between 1982 and 1984.
111
 The reported annual CPI reports 
changes relative to the reference index. For example, an index of 135 means a 35% increase in 
price since the reference period. Similarly, an index less than 100 reflects a decrease in price. 
Movements of the index from one date to another can be expressed as the difference between 
index levels, usually expressed as percent changes. The CPI allows for comparisons of consumer 
costs over time. Table 3.5 shows the CPI of medical care services that pertain to hospital and 
related services. 
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Table 3.5: Consumer Price Indices (CPI) for Hospital and Related Services 
Year CPI for Hospital and Related Services Percent change from 
previous year 
2006 468.1  
2007 498.9 6.58 
2008 534.0 7.04 
 
 
Independent variables 
 
The independent variables in the study were patient characteristics (age, race, gender, source of 
payment), 2) patient clinical conditions (admission status, severity of illness, discharge status, 
dialysis status), 3) physician characteristics (physician specialty), 4) hospital characteristics (bed 
size, geographical region). These variables have been selected based on a review of literature and 
their availability in the final dataset for this study. A description of independent variables for this 
study can be found in Table 3.6. 
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Table 3.6: Independent variables 
Variable  Description Variable name 
PATIENT 
CHARACTERISTICS 
Demographics 
 
Age  
 
 
Race 
 
 
Gender 
 
Source of payment 
 
 
 
Clinical conditions 
 
Admission status 
 
 
Severity of illness 
 
Discharge status 
 
 
Dialysis status 
 
 
 
 
 
18-30 years = 3, 31-50 years = 2,  
51-64 years = 1, >=65 years = 0 
 
White = 3, Hispanic = 2, Black = 1, 
Other = 0 
 
Male = 0, Female = 1 
 
Medicare = 3, Medicaid = 2, 
Commercial/Private payer = 1, Self-
pay = 3, Other = 0 
 
 
 
Elective = 2, Emergency = 1,Urgent = 
3, Other = 0 
 
Extreme = 0, Major = 1, Moderate = 2 
      
Expired = 2, Discharged/Transferred 
alive = 1, Other = 0 
 
On dialysis = 1, Not on dialysis = 0 
 
 
 
 
Age_group 
 
 
Race 
 
 
Sex 
 
Primary_payer 
 
 
 
 
 
Admission 
 
 
SOI 
 
Discharge_status 
 
 
Dialysis 
HOSPITAL 
CHARACTERISTICS 
 
Bed size 
 
 
 
Geographical region 
 
 
 
1-199 = 0, 200-399 = 1, 400-599 = 2, 
600-799 = 3, 800-999 = 4, 1000 or 
more = 5 
 
Midwest = 0, Northeast = 1, Southeast 
= 2, Southwest = 3, West = 4, 
Unknown = 5 
 
 
 
BedSize 
 
 
 
Region 
PHYSICIAN 
CHARACTERISTICS 
 
Physician specialty 
Internal medicine = 7, Surgery = 6, 
Hospitalist = 5, Pulmonary/Critical 
care = 4, Transplant = 3, Cardiology = 
2, Nephrology = 1, Other = 0 
Phys_specialty 
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Statistical analysis by objective 
Statistical analyses were performed using Statistical Analysis Software (SAS v. 9.2) and 
Predictive Analytical Software (PASW v. 17.0, previously SPSS) statistical software. Estimates 
for continuous variables were reported using Mean, Standard deviation and Ranges, and for 
categorical variables using Frequencies and Proportions. Proportions between the groups were 
compared using Pearson‟s chi-square. Continuous variables were compared using a t-test or a 
Wilcoxon Rank sum test depending on the variable‟s distribution. A two-sided alpha of 0.05 was 
considered significant. Following is a discussion of the statistical methods that was used to 
address each objective. 
Modeling economic data is complicated. Ordinary least squares (OLS) regression is not the 
optimal choice due to the nature of economic data.
112-114
 Firstly, observed cost data, is rarely 
normally distributed (positively skewed) and this violates the normality assumption necessary 
with OLS regression.
114, 115
 Secondly, with economic data the variance often increases as the 
mean increases due to the presence of heteroskedasticity (non-constant variance), violating the 
homogeneous variance assumption, hence making OLS inappropriate.
114, 115
  Various statistical 
solutions have been proposed to model charges more appropriately.  
A log transformation can be performed to make the observed cost data more normally 
distributed.  However, interpretation of resulting estimates may not be accurate, as it would be in 
„log costs‟, and not actual costs. Smearing factors used to transform economic data from 
logarithmic back to natural units can introduce substantial bias in the presence of 
heteroskedasticity.
88, 115
  
A generalized linear modeling (GLM) approach provides appropriate and flexible methods 
for analysis of mean costs that explicitly allow for the non-normal distribution of the data.
116
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GLMs have a variety of forms characterized by two features: a distribution function (F) for the 
outcome data and a link function (g) which describes the scale on which covariates in the model 
are related to the outcome.
117
 The most appropriate distributions for cost data would be the 
gamma or inverse Gaussian distribution.
116
 Both of these distributions are appropriate for non-
zero continuous outcomes. However, most economic data analysis utilizes the gamma 
distribution.
116
 The gamma distribution is appropriate since it assumes that variance is 
proportional to the square of the mean.  Economic data are non-zero, continuous and usually 
have a variance which increases with the mean. The negative binomial distribution would not be 
appropriate since it assumes a categorical outcome. The link function is not a transformation on 
the data, but a transformation of the population mean. The most commonly used link function for 
economic analysis is the log link.
116
 GLM using gamma distribution and log link is theoretically 
the preferred approach. Situations in which multiple observations are obtained from the same 
subjects or in the presence of clustered data, generalized estimating equations (GEE) within the 
framework of GLM are preferred. In a GEE, the researcher chooses a functional form 
(distribution) and link function as with any GLM, but then also chooses a covariance structure 
that adequately describes the known or suspected correlations between repeated observations. 
Commonly used types of covariance structures include exchangeable, autoregressive, dependent, 
independent and unstructured.  
Observational studies are aimed at investigating the effect of an exposure (treatment) by 
comparing outcomes for subjects not randomly assigned to the exposure of interest.
118
 In 
randomized clinical trials, random assignment to different treatments guarantees that on average 
there should be no systematic differences in observed or unobserved covariates so that the study 
groups are comparable with respect to the distribution of their covariates.
44
 However, in non-
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randomized observational studies, investigators have no control over treatment assignment, and 
therefore direct comparisons of outcomes from the treatment groups maybe misleading. The 
absence of random assignment can introduce systematic error into an observational study.  
Propensity scores are the conditional probability of exposure given measured baseline 
variables.
44
 Observational studies use this method to adjust for observable bias with the goal to 
eliminate bias from unequal distribution of confounders. The actual propensity score is estimated 
using a logit or probit model, where a group of potential confounders is converted into one scalar 
score. 
119
 The score is the probability (0 ≤ propensity score ≤ 1) of receiving the exposure (i.e., 
treatment) based on the set of identified covariates. The resulting score can be used as a 
matching or stratification factor, as a covariate in multivariable model or to perform inverse 
probability of exposure weighting.
45
 Each of these techniques is a way to make an adjustment for 
covariates prior to (matching and stratification) or while (stratification and regression 
adjustment) calculating the treatment effect.  
In order for propensity scoring to work efficiently, all covariates that affect both the 
treatment assignment and outcome must be included in the propensity score model, and all 
subjects must have some non-zero probability of receiving each treatment. This is referred to as 
the strongly ignorable assumption.
120
 The most crucial decision in propensity scores is which 
covariates to include in the propensity score model. Every effort must be made to ensure that all 
variables related to both the treatment and response, are included in the propensity score model. 
It is also very important not to include the response in the propensity score model. In theory, 
covariates that are known to be related to the treatment but not to the outcome should not be 
included because they may potentially reduce the effectiveness of the method used in balancing 
the distributions of confounding covariates.
44
 In practice, however, there may be covariates for 
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which this issue is not clear. Unimportant covariates can add noise to the model and inflate 
variance estimates, while omitting an important covariate can result in serious bias. Rubin et al., 
indicate that it is better to include an unimportant covariate and lose some efficiency than 
increase the bias by omitting an important covariate.
121
 Figure 3.2 is a suggested conceptual 
model adapted from Shever et al.
1
 as a guide for variable selection in propensity score analysis.  
Once the propensity score is calculated, it can be used as a matching or stratification factor, as a 
covariate in multivariable model or to perform inverse probability of exposure weighting.
45
 
Propensity scores can be used to match patients between exposure groups on multiple 
confounders. Matching is specifically performed  when the control group is larger than the cases 
and obtaining the response (outcome) is costly or otherwise very difficult; and when there are 
significant covariate differences between the two treatment groups.
118
 In whichever case, the 
possibility of over-matching and significant loss of cases/controls must be considered. This 
occurs when matching is done incorrectly or unnecessarily. The more variables used to calculate 
the propensity score, the greater the likelihood of overmatching. To avoid overmatching, the 
propensity score should preferably include only established confounders.
44,119,121
  
Sub-classifying or stratifying on propensity scores requires that subjects be grouped 
together or matched based on having similar covariate values. Once the strata are defined, treated 
(cases) and control subjects who are in the same stratum are compared directly. It is established 
that five strata based on the propensity score will remove over 95 per cent of the bias in each of 
these covariates. Stratification becomes difficult when many confounders are present since there 
are not enough observations in each stratum. Stratification on propensity score limits the number 
of stratum thus making stratification a more robust method to control for confounding.
44
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If the score is used in a multivariable model, the second part of the two-stage regression 
process is the traditional model where the dependent variable is the outcome of interest and the 
propensity score is used as a covariate. The advantage of including propensity scores over 
traditional regression is in not over-parameterizing the model.
122
 Normally each confounder 
would require one degree of freedom (df) while the propensity score, which could be comprised 
of many confounders, only requires 1 df. However, use of a continuous, linear score makes a 
strong assumption about the relationship between propensity and disease risk, and estimated 
treatment effects can be biased if this assumption does not hold.
120
 
Propensity scores have their own set of limitations. They do not balance unmeasured 
characteristics and confounders.  Large sample sizes are required for this methodology to work 
optimally.
118
 It only controls for unobserved covariates to the extent that they are correlated with 
the observed covariates. When creating the propensity score, strong and weak confounders are 
handled the same way in calculating the score. It is possible that a weak confounder has the same 
or larger coefficient in calculating the propensity score (e.g., a covariate having moderate 
association with treatment and weak association with outcome) than a stronger confounder (e.g., 
a covariate having moderate association with treatment and outcome). Additionally, covariates 
that are directly affected by the exposure of interest and not related to the outcome cannot be 
used in the propensity score model.
123
 Also, the models used to generate the propensity score 
rely on the same assumptions as logistic regression. If the model uses the propensity score as a 
continuous variable, the assumption of a (log-) linear association with the dependent variable 
must be tested using categories.
124
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Figure 3.2: Conceptual model for variable selection in propensity score analysis
Is the variable related to both the 
treatment and outcome variables? 
Propensity scores (generated from those 
independent variables thought to be confounders) 
Matching Covariance-
adjusted 
regression 
Stratification 
Regression Regression 
Outcomes 
-Total hospital 
costs 
- Length of stay 
Independent variables available for second step of 
propensity score analysis 
-Is the variable related to the outcome variable? 
Do not include variable 
in the analysis 
Methods 
Yes 
Yes 
No 
No 
Choose one of the three methods 
Potential confounders 
-Patient characteristics 
-Clinical conditions 
-Physician 
characteristics 
-Hospital characteristics 
-Treatment 
characteristics 
Treatment variable of interest (dichotomous) 
IV iron + ESA / ESA alone 
 
Adapted from Shever et al. 
1
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Statement and testing of research hypotheses by objective 
This section is presented in the form of objectives and statements of the research hypotheses in 
their null form (Ho), followed by a discussion of the statistical testing of the hypotheses. 
 
Objective 1a: Quantify the extent of utilization of IV iron in anemic chronic kidney disease 
patients  
H0-1a: There is no significant change in the utilization of IV iron and ESA over time. 
Objective 1b: Determine the prevalence of concomitant IV iron administration when 
Erythropoiesis Stimulating Agents (ESA) therapy is initiated 
H0-1b: There is no significant difference in the utilization of IV iron and ESA, compared to ESA-
therapy alone over time. 
The first research objective of this inquiry was to quantify the extent of utilization of IV iron and 
ESA use, relative to the use of ESA alone, for the time period between 2006 and 2008. The drug 
utilization over time provides informative data useful for prescribers, hospital administrators, and 
marketers. Studies highlighting changes in drug use are important to measure the impact of 
events occurring in a certain time period that influence such changes. 
A trend evaluation of the prevalence rate of usage of ESA and IV iron over time was 
performed for both the drugs. Differences between the study groups were calculated using t-tests, 
statistical significance set at p < 0.05. The days of therapy (DOTs) for ESA and IV iron therapy 
administered to individual patients was determined. The mean duration of therapy for each drug 
was calculated. The aggregate of drug use in each hospital for each year was expressed as DOTs 
per 100 patient-days (PDs). For example, if a patient received a single dose of a drug (ESA or IV 
iron) on a given day, whether or not multiple doses are usually administered, it was registered as 
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1 DOT. If a patient received more than 1 ESA drug (epoetin or darbepoetin) on the same day, it 
was counted as 1 DOT for ESA therapy. Days of hospitalization for each patient at each hospital 
were summed to provide total patient-days (PDs).  
 
Objective 2: Determine predictors of IV iron use among the domains of patient characteristics, 
clinical conditions, physician characteristics, and hospital characteristics  
H0-2: There exists no significant association between patient characteristics, clinical conditions, 
physician characteristics, or hospital characteristics and IV iron and ESA use relative to ESA 
use alone.  
A clustered binomial logistic regression model (Eqn. 1) using the GEE methodology was used to 
identify the predictors of IV iron use. The dependent variable was drug use, and the independent 
variables to be included in the model were 1) patient characteristics (age, race, gender, length of 
stay, primary payer), 2) patient clinical conditions (admission status, severity of illness, 
discharge status, dialysis status), 3) physician characteristics (physician specialty), 4) hospital 
characteristics (total hospital costs). A Wald‟s statistic was used to test the significance of 
regression coefficients. The relationship between variables described above was evaluated for 
statistical significance. Comparisons were considered statistically significant at p < 0.05. 
 
IV iron + ESA/ESA-alone = β0 + β1Patient Demographics + β2Patient Clinical Characteristics + 
β3Hospital Characteristics +β4Physician Specialty + e…….Eqn. 1 
 
A goodness of fit test (QIC and QICC) was performed and was used to evaluate how well the 
model fits the observations.
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 This was then useful in determining which of the correlation 
structures was more appropriate and the best subset of predictors. A Huber-White sandwich 
estimator (robust estimator) was used as a way to ensure that the variances were robust. 
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Specifically, robust variances are important as they provide accurate assessments of the sample-
to-sample variability of the parameter estimates even if the model is misspecified.
126
  
For the test of model effects, Type III, was selected for all analysis as it does not depend on the 
entry order of the variables like Type I does. Test Type III is typically preferred unless order of 
the variables is important, which in this case it is not. 
 
Objective 3: Determine the impact of IV iron and ESA use vs. ESA use alone on length of stay 
(LOS) while adjusting for confounders 
H0-3: Given other things constant, patients with anemia of CKD on ESA therapy alone incur 
greater LOS compared to patients on IV iron +ESA therapy. 
The impact of drug use on LOS will be calculated using a GEE with a gamma distribution and a 
log link while adjusting for various factors. Known confounders and potential covariates will be 
eligible for inclusion. In the first step, a clustered binomial logistic regression model using the 
GEE methodology was used to calculate the propensity scores. Considering the characteristics of 
individual hospitals, hospital ID was used as a cluster variable in the GEE to account for 
correlations of drug utilization patterns, costs, LOS etc. of patients from the same hospital. This 
model includes age, gender, race, primary payer, physician specialty, severity of illness, 
discharge status, dialysis status as the independent variables and the treatment variable (ESA +IV 
iron and ESA alone) as the dependent variable. A propensity score was estimated for each 
subject based on the values of the observed covariates using the clustered logistic regression. The 
observations were then stratified by quintiles of the distribution of the estimated propensity 
scores. Chi-square tests of independence between treatment assignment and each categorical 
predictor, and t-tests of equality of means with the treatment assignment as the classification 
variable and continuous covariates as response variables were done within each strata to test the 
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success of the propensity-score model in balancing the covariates. In the second step, 
multivariable regression analysis using GEE methodology was performed to assess the length of 
stay (LOS) associated with the use of IV iron while controlling for the propensity quintile. 
Inclusion of quintile in the model inherently controls for all factors included in the propensity 
model. The conceptual model (Figure 3.2) was used as a guide to variable selection for the 
propensity score analysis. Using the predicted values from the multivariable regression model, 
the mean LOS of IV iron + ESA use was subtracted from the mean LOS of ESA use alone.  
 
Objective 4: Determine the impact of IV iron and ESA use vs. ESA use alone on total hospital 
costs while adjusting for confounders 
H0-4: Given other things constant, patients with anemia of CKD on ESA therapy alone incur 
greater total hospital costs compared to patients on IV iron +ESA therapy. 
The impact of drug use on hospital costs was calculated using a GEE with a gamma distribution 
and a log link while adjusting for various factors. Known confounders and potential covariates 
were included. In the first step, a clustered binomial logistic regression model using the GEE 
methodology was used to calculate the propensity scores. Considering the characteristics of 
individual hospitals, hospital ID was used as a cluster variable in the GEE to account for 
correlations of drug utilization patterns, costs, LOS etc. of patients from the same hospital. This 
model included age, gender, race, hospital level factors (total hospital costs), primary payer, 
physician specialty, severity of illness, discharge status, dialysis status as the independent 
variables and the treatment variable (ESA +IV iron and ESA alone) as the dependent variable. A 
propensity score was estimated for each subject based on the values of the observed covariates 
using the clustered logistic regression. The observations were then stratified by quintiles of the 
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distribution of the estimated propensity scores. Chi-square tests of independence between 
treatment assignment and each categorical predictor, and t-tests of equality of means with the 
treatment assignment as the classification variable and continuous covariates as response 
variables were done within each strata to test the success of the propensity-score model in 
balancing the covariates. In the second step, multivariable regression analysis was performed to 
assess the total hospital costs associated with the use of IV iron while controlling for the 
propensity quintile. Inclusion of quintile in the model inherently controls for all factors included 
in the propensity model. The conceptual model (Figure 3.2) was used as a guide to variable 
selection for the propensity score analysis. Using the predicted values from the multivariable 
regression model, the mean hospital costs of IV iron + ESA use was subtracted from the mean 
hospital costs of ESA use alone. 
 
Human subjects’ protection and data privacy 
VCU IRB exemption is obtained for this study. A dataset was constructed from the University 
Health System Consortium (UHC) data warehouse. To ensure minimal risk to the patients, the 
data has been coded and encrypted. Access to the dataset was restricted to those individuals 
listed on this protocol, and the dataset was centrally maintained in a password-protected 
environment. Disclosure of any kind of information did not take place without the expressed 
written permission of UHC or as required by law. Results will be published in such a way that no 
subject will be individually identifiable. Data within UHC‟s Clinical Resource Manager is 
compliant with the Health Insurance Portability and Accountability Act of 1996 (HIPAA). This 
study qualified for exemption according to 45 CFR 46.101(b) Category 4 at Virginia 
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Commonwealth University internal review board (IRB). (VCU IRB#: HM12609). A copy of the 
IRB Approval form can be found in the Appendix A. 
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CHAPTER 4 
 
Results 
 
 
The results of this inquiry are presented in this chapter. The results have been summarized into 
the following sections: 
 
Data manipulation 
 Outlier analysis 
 Hospital cost adjustment by Consumer Price Index  
 
Descriptive Statistics 
 brief descriptive summary of IV iron and ESAs 
 summary statistics of patient and hospital characteristics characterizing drug use 
 
Utilization and days of therapy for ESA and IV iron over the study time period 
 overall prevalence of IV iron and ESA  use across hospitals 
 t-tests and ANOVA to understand utilization of IV Iron and ESA relative to ESA alone 
 
Predictors of Off-label Uses 
 clustered binomial logistic regression using the GEE methodology 
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Impact of IV iron and ESA use versus ESA use alone on length of stay while adjusting for 
confounders 
 generalized estimating equation to estimate length of stay while adjusting for 
confounders using propensity scores 
 
Impact of IV iron and ESA use versus ESA use alone on total hospital costs while adjusting for 
confounders 
 generalized estimating equation to estimate total hospital costs while adjusting for 
confounders using propensity scores 
 
 
Data Manipulation 
 
Before further analysis (n = 84,447), the dataset was examined for erroneous data points. Some 
observations existed with a negative LOS. These observations were removed. Some observations 
reported incredibly low costs (less than $100) in spite of having a long LOS. The data were 
explored but there was no apparent pattern to the low costs. The investigator chose a reasonably 
conservative criterion that would exclude patients with low and high extremes in hospital costs 
or length of stay. The 1
st
 and 99
th
 percentile patients were deleted since they were mainly outliers 
with extremely low or extremely high cost (< $100 or > $300,000) and LOS (> 70 or 0 days) 
values. Also, patients with missing values for hospital costs and LOS were dropped from further 
analyses (N = 82,497). 
Hospital costs were inflated to their 2008 value. CPI adjusted rates (compounded annually) 
were calculated for each year. Table 4.1 assumed a $1.00 reference value. Total hospital costs 
were adjusted to the 2008 value by multiplying the reported cost by the CPI adjusted rate. For 
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example, 2006 values were increased by 6%, and 2007 values by 13% to estimate their 2008 
value. Figure 4.1 shows step by step how the CPI adjusted rates were calculated. The inflation 
rates can be found in Table 4.1. 
Table 4.1: CPI adjusted rates 
 2006 to 2008 2007 to 2008 
2006 1  
2007 1.06 1 
2008 1.13 1.07 
 
 
Figure 4.1: Calculation of CPI adjusted rate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Calculation of CPI adjusted rate 
 
2006 to 2007 had an inflation rate of 6.58% 
2007 to 2008 had an inflation rate of 7.04% 
Assuming the value in 2006 was $1, the value in 2007 would be: 
$1.00 x (1 + 0.0658) = $1.06 
The value in 2008 would be: $1.06 x (1 + 0.0704) = $1.13. 
This means that the adjusted inflation rate for 2006 to 2007 was 
6% and for 2006 to 2008 was 13%. 
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Summary Description of Sample Characteristics by Drug Usage 
 
Demographic data for the categorical variables (age, race, sex, admission source, payer type, 
admission status, severity of illness, discharge status, physician specialty, bed size and 
geographical region of hospital, ESA and IV iron type) are described in Tables 4.2. Of the 
82,947 patients, 76,270 were ESA users (92%) and 6678 (8%) were IV iron + ESA users. 
Overall, white males in the higher age group (> 50 years) made up the largest demographic 
subgroup. The majority of patients in both drug use groups had Medicare as their primary payer.  
There was a significant difference between the ESA users and IV iron + ESA users with 
respect to all the patient demographic characteristics, clinical characteristics, physician 
characteristics and hospital characteristics.  
The age of patients ranged from 18 to more than 65 years. Middle aged (31-50 years) and 
higher age groups ranging from 51-65 years or more comprised the largest group of patients, 
although there were patients in all age categories as shown in Table 4.2. More IV iron users were 
in the elderly age group ( ≥ 65 years) than ESA users (χ2 = 76.04, df = 3, p-value < 0.0001). The 
majority of the patients were admitted as “Emergency” patients to the hospital, and more IV iron 
users were admitted as “Emergency” than the ESA users alone (χ2 = 76.73, df = 3, p-value < 
0.0001). More than half of the patients were in the “Major” severity of illness category; 58% of 
IV iron users were “majorly” sick as compared to 54% of ESA users (χ2 = 24.88, df = 2, p-value 
< 0.0001). Discharge status was examined strictly as alive, dead or not available. More IV iron 
users were discharged and more ESA users expired in the hospital. The majority of the patients 
were discharged or transferred alive from a UHC hospital. Higher percentage of ESA users 
(4.5%) expired in the hospital compared to 3.5% of IV iron (χ2 = 14.56, df = 2, p-value = 0.0007). 
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The prescribing patterns for IV iron and ESA drugs were studied based on physician specialty as 
shown in Table 4.2. Internal medicine physicians and nephrologists prescribed the study drugs to 
a greater extent than any other specialists or surgeons. Univariate chi-square tests showed 
statistically significant difference across the two drug groups and the physician specialty 
categories. 
  In the study sample, patients admitted to hospitals located in the Midwest and the 
Northeast received the drugs to a greater extent than patients in any other region. IV iron 
utilization was the lowest in the Southwestern region of the U.S and highest in the Midwestern 
region. Overall the drug utilization was quite similar across hospital bed size categories. 
Univariate chi-square tests showed statistically significant differences between IV iron + ESA 
users and ESA user groups for the hospital characteristics such as the bed size and the hospital 
geographical region. 
In terms of drug use, the majority of the patients received epoetin as their ESA therapy. More 
patients in the ESA alone group received epoetin compared to patients in the IV iron group (χ2 = 
105.93, df = 1, p-value < 0.0001). Within the IV iron group (n = 6678), 85% patients received 
iron sucrose and only 15% patients received iron dextran as their IV iron supplementation.  
Descriptive data for the continuous variables can be found in Table 4.3. Data is reported 
as medians and interquartile ranges since the variables were not normally distributed. The 
Wilcoxon Rank Sum test indicated both the continuous variables were significantly different 
between the IV iron and ESA and ESA alone groups. Information on mean costs and LOS is 
shown to provide an estimate of the unadjusted difference in mean costs and LOS between the 
two drug groups. 
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Table 4.2: Descriptive statistics for categorical variables 
Variable ESA + IV Iron  
n (column%) 
ESA alone 
N (column%) 
 Total Pearson Chi-
Square  
Patient 
characteristics 
    
                               N (%)               n (%)             N p < 0.05 
Age group (years) 
18-30 
 
31-50 
 
51-64 
 
≥65 
 
Total 
 
369 (5.53) 
 
1476 (22.10) 
 
2074 (31.06) 
 
2759 (41.31) 
 
6678 
 
4728 (6.20) 
 
19349 (25.37) 
 
24,546 (32.18) 
 
27647 (36.25) 
 
76269 
 
5097 (6.14) 
 
20825 (25.11) 
 
26620 (32.09) 
 
30406 (36.66) 
 
82497 
76.04, p<0.0001 
 
Race 
White 
 
Black 
 
Hispanic 
 
Other 
 
Total 
 
3348 (50.13) 
 
2299 (34.43) 
 
514 (7.70) 
 
517 (7.74) 
 
6678 
 
30504 (40) 
 
32010 (41.97) 
 
7742 (10.15) 
 
6013 (7.88) 
 
76269 
 
33852 (40.81) 
 
34310 (41.36) 
 
8256 (9.95) 
 
6530 (7.87) 
 
82947 
276.49, p<0.0001 
 
Gender 
Male 
 
Female 
 
Total 
 
3615 (54.13) 
 
3063 (45.87) 
 
6678 
 
39940 (52.37) 
 
36330 (47.63) 
 
76269 
 
43555 (52.51) 
 
39393 (47.49) 
 
82947 
7.68, p=0.0056 
Primary payer 
Commercial/ 
Private payer 
 
Medicare 
 
Medicaid 
 
Self-pay 
 
Other 
 
Total 
 
1157 (17.33) 
 
 
4588 (68.70) 
 
710 (10.63) 
 
97 (1.45) 
 
126 (1.89) 
 
6678 
 
11092 (14.54) 
 
 
53834 (70.58) 
 
9026 (11.83) 
 
924 (1.21) 
 
1394 (1.83) 
 
76269 
 
12249 (14.77) 
 
 
58422 (70.43) 
 
9736 (11.74) 
 
1021 (1.23) 
 
1520 (1.83) 
 
82947 
45.85, p<0.0001 
Patient clinical conditions 
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Admission status 
Emergency 
 
Urgent 
  
Elective 
 
Other 
 
Total 
 
4130 (61.84) 
 
1436 (21.50) 
 
1017 (15.23) 
 
95 (1.42) 
 
6678 
 
44360 (58.16) 
 
20015 (26.24) 
 
10636 (13.95) 
 
1259 (1.65) 
 
76269 
 
48490 (58.46) 
 
21451 (25.86) 
 
11653 (14.05) 
 
1354 (1.63) 
 
82947 
76.73, p<0.0001 
Severity of illness 
Moderate 
 
Major  
 
Extreme 
 
Total 
 
817 (12.32) 
 
3859 (57.79) 
 
2002 (29.98) 
 
6678 
 
10205 (13.38) 
 
41673 (54.64) 
 
24392 (31.98) 
 
76269 
 
11022 (13.29) 
 
45532 (54.89) 
 
26394 (31.82) 
 
82947 
24.88, p<0.0001 
Discharge status 
 
Discharged/Transf
erred alive 
 
Expired 
 
Other 
 
Total 
 
 
6440 (96.44) 
 
 
236 (3.53) 
 
2 (0.03) 
 
6678 
 
 
72782 (95.43) 
 
 
3461 (4.54) 
 
26 (0.03) 
 
76269 
 
 
79222 (95.51) 
 
 
3697 (4.46) 
 
28 (0.03) 
 
82497 
14.56, p=0.0007 
Dialysis status 
 On dialysis 
 
Not on dialysis  
 
Total 
 
1776 (26.59) 
 
4902 (73.41) 
 
6678 
 
23546 (30.87) 
 
52724 (69.13) 
 
76269 
 
25322 (30.53) 
 
57626 (69.47) 
 
82947 
52.96, p<0.0001 
Physician characteristics 
Physician 
specialty 
Internal Medicine 
 
Nephrology 
 
Cardiology 
 
Transplant 
 
Pulmonary/Critical  
 
 
2182 (32.67) 
 
1319 (19.75) 
 
750 (11.23) 
 
273 (4.09) 
 
196 (2.94) 
 
 
25652 (33.63) 
 
12793 (16.77) 
 
8141 (10.67) 
 
3696 (4.85) 
 
2635 (3.45) 
 
 
27834 (33.56) 
 
14112 (17.01) 
 
8891 (10.72) 
 
3969 (4.78) 
 
2831 (3.41) 
64.28, p<0.0001 
 64 
 
Care 
 
Hospitalist 
 
Surgery 
 
Total 
 
 
320 (4.79) 
 
823 (12.32) 
 
6678 
 
 
3391 (4.45) 
 
9260 (12.14) 
 
76269 
 
 
3711 (4.47) 
 
10083 (12.16) 
 
82947 
Hospital characteristics 
Bed size 
1-399 
 
400-599 
 
600-799 
 
800 or more 
 
Total 
 
1728 (25.88) 
 
1281 (19.18) 
 
2005 (30.02) 
 
1664 (24.92) 
 
6678 
 
12309 (16.14) 
 
22099 (28.98) 
 
25584 (33.54) 
 
16278 (21.34) 
 
76269 
 
14037 (16.92) 
 
23380 (28.19) 
 
27589 (33.26) 
 
17942 (21.63) 
 
82947 
612.08, p<0.0001 
Geographical 
region 
Midwest 
 
Northeast 
 
Southeast 
 
Southwest 
 
West 
 
Total 
 
 
2416 (36.18) 
 
1826 (27.34) 
 
848 (12.70) 
 
456 (6.83) 
 
1132 (16.95) 
 
6678 
 
 
17498 (22.94) 
 
17045 (22.35) 
 
17264 (22.64) 
 
10879 (14.26) 
 
13583 (17.81) 
 
76269 
 
 
19914 (24.01) 
 
18871 (22.75) 
 
18112 (21.84) 
 
11335 (13.67) 
 
14715 (17.74) 
 
82947 
1044.15, 
p<0.0001 
Treatment characteristics 
ESA type 
Epoetin 
 
Darbepoetin 
 
Total 
 
3428 (51.3) 
 
2082 (31.2) 
 
6678 
 
44106 (57.8) 
 
33393 (43.8) 
 
76269 
 
47534 (57.3) 
 
35475 (42.8) 
 
82947 
105.93,  
p<0.0001 
IV iron type 
Iron sucrose 
 
Iron dextran 
 
Total  
 
5678 (85) 
 
1000 (15) 
 
6678 
 
NA 
 
NA 
 
NA 
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Table 4.3: Descriptive statistics for continuous variables 
 IV Iron +ESA therapy ESA therapy alone 
Variable Mean (SD) Median IQR Mean 
(SD) 
Median IQR p-value 
Total hospital 
costs 
34933 20014 10412-
43330 
31278 17058 8877-
36656 
<0.0001 
LOS 10.7 7 4-14 9.6 7 3-12 <0.0001 
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Objective 1: 
Trends for IV iron and ESA use and days of therapy 
 
Detailed description of IV iron use by patient demographics, patient clinical conditions, 
physician specialty, hospital characteristics and treatment characteristics is given in Table 4.2. 
This section describes the overall prevalence and trends in use for IV iron and ESA therapy from 
2006-2008. Of the 82,947 CKD patients using ESA, only 6678 patients were prescribed IV iron. 
Figure 4.2 displays the overall time trend in IV iron and ESA therapy use in CKD patients. 
The figure 4.2 shows a steady increasing trend in the use of ESA therapy from 2006 to 
2007. The use of ESA therapy (ESA alone) gradually decreased from the last quarter of 2007 to 
2008. There was a steady increase in the use of IV iron therapy in CKD patients already on ESA. 
Comparing the two therapeutic groups, fewer patients used IV iron along with ESA from 2006 to 
the second quarter of 2007. There was a notable increase in the number of patients using IV iron 
along with ESA as compared to ESA alone from the third quarter of 2007 to 2008.  
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Figure 4.2: Trend showing IV iron and ESA use from 2006-2008 
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Within the sample of patients on IV iron, 85% (n = 5678) of the patients received iron sucrose, 
and the remaining 15% (n = 1000) received iron dextran. Annual percentages of CKD patients 
prescribed IV iron, in addition to ESA therapy from 2006 to 2008 are listed in Table 4.4. IV iron 
use in dialysis patients, and also in CKD patients not on dialysis, increased sharply from 2006 to 
2008. Of all the patients that got IV iron (n = 6678), only 26% of the patients were on dialysis. In 
2006, amongst the patients on hemodialysis, 91% patients were prescribed iron sucrose and only 
9% were prescribed iron dextran. A similar trend was followed in 2007 and 2008, where iron 
sucrose was more often used as compared to iron dextran.  
Table 4.4: Annual percentages of patients treated with IV iron 
 2006 2007 2008 
Hemodialysis  
Total number of patients 
Iron sucrose (%) 
Iron dextran (%) 
 
Peritoneal dialysis 
Total number of patients 
Iron sucrose (%) 
Iron dextran (%) 
 
395 
359 (91) 
36 (9) 
 
 
17 
10 (41) 
7 (59) 
 
544 
514 (94) 
30 (6) 
 
 
18 
16 (89) 
2 (11) 
 
779 
718 (92) 
61 (8) 
 
 
23 
19 (83) 
4 (17) 
 
 
Not on dialysis 
Total number of patients 
Iron sucrose (%) 
Iron dextran (%) 
 
1197 
923 (77) 
274 (23) 
 
1516 
1263 (83) 
253 (17) 
 
2189 
1856 (85) 
333 (15) 
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IV iron and ESA days of therapy 
The days of therapy (DOTs) for ESA and IV iron therapy administered to individual patients was 
determined. The mean duration of therapy for each drug was calculated. The aggregate of drug 
use for each year was expressed as DOTs per 100 patient-days (PDs). Table 4.5 lists the mean 
DOTs/100 PDs for IV iron and ESA therapy. The mean (±SD) ESA DOTs/100 PDs was 12.36 
±21.92 in the ESA group and 8.66 ±20.28 in the IV iron group. T-test results showed a 
statistically significant mean difference of 3.7 [(95% CI = 3.15, 4.24), SE = 0.278, p < 0.0001].  
 
Table 4.5: Mean days of therapy/100 patient days by drug group 
 IV Iron +ESA therapy ESA therapy alone 
Variable Mean SD Mean SD p-value 
ESA DOT/ 100 PDs   8.66 20.28 12.36 21.92 <0.0001 
IV Iron DOTs/100 PDs 30.41 28.20 NA NA NA 
 
Figure 4.4 shows change in the mean ESA DOTs/100 PDs with each quarter of drug use from 
2006-2008. There is a significant increase in the mean ESA use in the first quarter of 2006 (p = 
0.032). Notice the significant (p = 0.005) decrease in the use of ESA from the second quarter of 
2006 to the third quarter of 2007. A substantial drop in the mean use of ESA occurred from the 
third quarter of 2006 to the first quarter of 2008 (p<0.0001). 
Figure 4.5 shows the change in the mean IV Iron DOTs/100PDs with each quarter of 
drug use from 2006-2008. Note the significant increase of IV iron use from the first quarter of 
2007 to the second quarter of 2008 (p < 0.0001). 
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Figure 4.3: Mean ESA DOTs/100 PDs use (with 95% CI) from 2006-2008 (by each quarter) 
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Figure 4.4: Mean IV Iron DOTs/100 PDs use (with 95% CI) from 2006-2008 (by each quarter) 
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Objective 2: 
Predictors of IV iron use 
 
The objective of the second research question was to determine predictors of IV iron and ESA 
use relative to ESA use alone. Based on the literature review and clinical relevance several 
component hypotheses were postulated a priori, which address the possible antecedents of drug 
use  in CKD patients as described in Table 4.2 which can be found in the second chapter. The 
variables included in the model came from four main domains: 
 
Patient demographic characteristics: Patient demographics included were age, race, gender 
and primary payer. The variable age was categorized into different age groups; „adult‟ (18 to 30 
years), „middle-aged‟ (31 to 50 years), „young old‟ (51 to 64 years) and „old old‟ (65 years and 
above). The reference category used for age group was adults aged between 18 and 30 years. The 
gender base category was male. The primary payer variable included Medicare, Medicaid, some 
commercial/private payer, and self-pay categories. Medicare was the reference category. The 
variable race included White, Black and Hispanics, with White as the reference category.  
 
Patient clinical characteristics: These included admission status, severity of illness, dialysis 
status, length of stay and discharge status. Admission status was categorized into „emergency‟, 
„urgent‟ and „elective‟, with „urgent‟ being the reference category. Severity of illness was 
categorized into „moderate‟, „major‟ and „extreme‟, and „moderate‟ was used as the reference 
category. The dialysis base category was „not on dialysis‟. Discharge status was categorized into 
„discharged/transferred alive‟ or „expired‟, and „expired‟ was used as a reference category.  
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Physician characteristics: The only physician characteristic used in the regression model was 
the physician specialty. Physicians were categorized into Internal medicine, Nephrology, 
Cardiology, Transplant, Pulmonary/Critical care, Hospitalists, and Surgeons, with Internal 
Medicine as the reference category. 
 
Hospital characteristics: These included the total hospital costs. Other variables available were 
the bed size and the region where the hospital was located. However, addition of these variables 
to the model seriously affected the overall fit of the model. Hence, predictors of drug use were 
estimated without these variables. Fit was assessed using the Quasi-likelihood under 
Independence Criterion (QIC) and Corrected Quasi-likelihood under Independence Criterion 
(QICC). QIC was used for choosing the best working correlation structure assumption, and 
QICC was used for choosing the best subset of predictors in the GEE model. Lower QIC and 
QICC values imply a better fit model.  
 
A clustered binomial logistic regression model (Eqn. 1) using the GEE methodology was used to 
identify the predictors of IV iron use. We put a restriction that patients within a hospital are 
nested and related when compared with patients between different hospitals, especially with 
respect to treatment patterns. The dependent variable was drug use, and the independent 
variables to be included in the model were 1) patient characteristics (age, race, gender, length of 
stay, source of payment), 2) patient clinical conditions (admission status, severity of illness, 
dialysis status, discharge status), 3) physician characteristics (physician specialty), 4) hospital 
characteristics (total hospital costs). A Wald‟s statistic was used to test the significance of 
regression coefficients. The relationship between variables described above was evaluated for 
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statistical significance. Comparisons were considered statistically significant at p < 0.05. No 
pairwise multicollinearity was found.  
 
IV iron + ESA/ESA-alone =β0 + β1Patient Demographics + β2Patient Clinical Characteristics + 
β3Hospital Characteristics +β4Physician Specialty + β5Drug Characteristics + e…….Eqn. 1 
 
The reference categories for each of the categorical independent variables in the model made up 
of White males prescribed ESA, and having Medicare as their drug coverage. All the patients in 
the reference category were admitted as “Urgent” patients with moderate severity of illness, who 
were not on dialysis, were seen by Internal Medicine physicians and expired on discharge.  
The results in Tables 4.6 to 4.8 belong to the same binomial logistic regression model and 
have been divided into 3 tables for ease of understanding.  
 
Patient Demographics 
 
The regression results of patient demographics as possible predictors of IV drug use have been 
summarized in Table 4.6. Older adults (>= 65 years) were 1.246 times more likely to be 
prescribed IV iron for anemia of CKD compared to young adults in the age range of 18-30 years 
[95% CI (1.108, 1.402), p < 0.0001]. Race was found to be a strong predictor of drug use in the 
anemic CKD population The Blacks and the Hispanics were 0.685 [95%CI (0.647, 0.726) p < 
0.0001)] times and 0.627 [95%CI (0.567, 0.695) p < 0.0001)] times as likely to receive IV iron 
compared to the White population on ESA therapy.  Patients covered under the Medicaid, any 
commercial/private insurance or who paid out of pocket for insurance were 1.141 [95%CI 
(1.044, 1.247) p = 0.003)], 1.265 [95%CI (1.178, 1.360) p < 0.0001)]  and 1.451 [95%CI (1.171, 
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1.798) p = 0.001)] times more likely to receive IV iron therapy as compared to patients covered 
under Medicare. 
 
Table 4.6: Binomial logistic regression with Drug use (IV Iron + ESA vs. ESA) as dependent 
variable and Patient demographics as Independent variables 
Parameter β exp(β) Standard 
Error 
Wald Chi-
square 
p-value 
Age group (Base 18-30 
years) 
31-50 years 
51-64 years 
>= 65 years 
 
 
-0.0260 
0.042 
0.220 
 
 
0.974 
1.043 
1.246 
 
 
0.0608 
0.0595 
0.06 
 
 
0.183 
0.498 
13.451 
 
 
0.669 
0.480 
<0.0001 
Gender (Base-Female) 
Male 
 
-0.031 
 
0.969 
 
0.026 
 
1.423 
 
0.233 
Race (Base-White) 
Black 
Hispanic 
Other 
 
-0.378 
-0.466 
-0.238 
 
0.685 
0.627 
0.788 
 
0.0295 
0.0517 
0.0497 
 
164.889 
81.154 
22.959 
 
<0.0001 
<0.0001 
<0.0001 
Primary Payer (Base-
Medicare) 
Medicaid 
Commercial/Private 
Self-pay 
Other 
 
 
0.132 
0.235 
0.372 
0.210 
 
 
1.141 
1.265 
1.45 
1.234 
 
 
0.0452 
0.0366 
0.1096 
0.0960 
 
 
8.535 
41.297 
11.543 
4.795 
 
 
0.003 
<0.0001 
0.001 
0.029 
 
 
Patient clinical characteristics 
 
Patient admission status, severity of illness, dialysis status and patient length of stay were strong 
predictors of drug use in the anemic CKD population (Table 4.7). Patients admitted to the 
hospital as emergency and elective cases were 1.34 [95%CI (1.256, 1.430) p < 0.0001)] times 
and 1.307 [95%CI (1.202, 1.421) p < 0.0001)] times more likely to be prescribed IV iron as 
compared to patients admitted to the hospital as urgent cases. „Extremely‟ sick CKD patients 
were less likely to receive IV iron as compared „moderately‟ sick patients. CKD patients not on 
dialysis were 0.851 [95%CI (0.8, 0.907) p < 0.0001)] times as likely to receive IV iron as 
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compared to CKD patients on dialysis. As the length of stay increased, CKD patients were more 
likely to receive IV iron.  [1.007, p < 0.0001)] 
Table 4.7: Binomial logistic regression with Drug use (IV Iron + ESA vs. ESA) as dependent 
variable and Patient clinical characteristics as Independent variables 
Parameter β exp(β) Standard 
Error 
Wald Chi-
square 
p-value 
Admission status 
(Base-Urgent) 
Emergency 
Elective 
Other 
 
 
0.293 
0.268 
0.088 
 
 
1.34 
1.307 
1.092 
 
 
0.0331 
0.047 
0.1110 
 
 
78.316 
39.305 
0.636 
 
 
<0.0001 
<0.0001 
0.425 
Severity of Illness 
(Base-Moderate) 
Major 
Extreme 
 
 
0.073 
-0.182 
 
 
1.075 
0.833 
 
 
0.0409 
0.0485 
 
 
3.142 
14.142 
 
 
0.076 
<0.0001 
Dialysis status (Base-
Not on dialysis) 
On dialysis 
 
 
-0.161 
 
 
0.851 
 
 
0.0319 
 
 
25.386 
 
 
<0.0001 
Discharge status (Base-
Expired) 
Discharged/Transferred 
alive 
Other 
 
 
0.012 
 
-0.323 
 
 
1.012 
 
0.724 
 
 
0.7383 
 
0.7426 
 
 
0.000 
 
0.189 
 
 
0.987 
 
0.664 
LOS 0.007 1.007 0.0020 11.923 0.001 
 
 
 
Physician and hospital characteristics 
 
Physician specialty and total hospital costs were significant predictors of drug use in this 
population (Table 4.8). Nephrologists were 1.216 [95%CI (1.131, 1.308) p < 0.0001)] times 
more likely to prescribe IV iron to CKD patients already on ESA therapy, compared to Internal 
Medicine physicians. Transplant specialists and surgeons were 0.772 [95%CI (0.664, 0.898) p = 
0.001)] and 0.912 [95%CI (0.836, 0.995) p = 0.038)] times as likely to prescribe IV iron to CKD 
patients compared to internal medicine physicians. As the total hospital costs increased, CKD 
patients were more likely to receive IV iron [1.007, p < 0.0001)]. 
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Table 4.8: Binomial logistic regression with Drug use (IV Iron + ESA vs. ESA) as dependent 
variable and Physician and hospital characteristics as Independent variables 
Parameter β exp(β) Standard 
Error 
Wald Chi-
square 
p-value 
Physician specialty 
(Base- Internal 
Medicine) 
Nephrology 
Cardiology 
Transplant 
Pulmonary/Critical Care 
Surgery 
Hospitalist 
Other 
 
 
 
0.196 
-0.050 
-0.259 
-0.137 
-0.092 
0.049 
-0.094 
 
 
 
1.216 
0.951 
0.772 
0.872 
0.912 
1.05 
0.91 
 
 
 
0.0371 
0.0463 
0.0772 
0.0798 
0.0442 
0.0631 
0.0431 
 
 
 
27.748 
1.182 
11.218 
2.932 
4.32 
0.612 
4.729 
 
 
 
<0.0001 
0.277 
0.001 
0.087 
0.038 
0.434 
0.03 
 
Total hospital costs 
 
2.226
E-6 
 
1.00 
 
5.4354E-
7 
 
16.770 
 
<0.0001 
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Objective 3: 
Adjusted difference in hospital costs by drug group 
 
A GEE utilizing a gamma distribution and logarithmic link was used to estimate total hospital 
costs while adjusting for potential confounders, while clustering for hospitals. Before a 
multivariate model could be analyzed, a propensity score was calculated for bias adjustment.  
A propensity score was calculated for the patient baseline covariates such as age, race, 
gender, primary payer, admission status, severity of illness, dialysis status, discharge status, and 
physician specialty using a clustered binomial logistic regression. The analysis was clustered by 
hospital ID to account for any correlations between patients in the same hospital. The 
independent variable was drug group (IV iron and ESA or ESA alone) and the dependent 
variables were the covariates mentioned above. Hospital level variables were not included in the 
propensity score analysis, and were used in the final multivariate model. Propensity scores were 
only calculated for 81,565 patients since 932 patients had missing data on admission status and 
discharge status variables. The model with the lowest Quasi-likelihood under Independence 
Criterion (QIC) and Corrected Quasi-likelihood under Independence Criterion (QICC) was 
selected for analysis. QIC was used for choosing the best working correlation structure 
assumption, and QICC is used for choosing the best subset of predictors in the GEE model. A 
lower QIC and QICC values imply a better fit model. 
The distribution of propensity scores is shown in Figure 4.5. Table 4.9 shows a list of 
covariates used in the propensity score analysis along with results of chi-square tests indicating 
significant differences between the two drug user groups on baseline covariates.  
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Figure 4.5: Distribution of propensity scores for IV iron and ESA user groups 
 
 
The observations were stratified by quartiles based on their propensity scores. The selection of 4 
sub-groups was based on an iterative process of testing the overall balance of covariates by 
stratifying into 3 to 10 sub-groups. Stratifying the propensity scores into 4 sub-groups provided 
maximum success in balance between the two drug groups on the baseline covariates within each 
stratum. 
Table 4.9 depicts the balance of covariates between the two drug groups, within each 
quartile. The baseline covariates were well balanced within the propensity score quartiles. Within 
individual quartiles, few characteristics had statistically significant different distributions. 
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Imbalance between drug groups was rectified by collapsing categories for categorical variables 
such as physician specialty, race, and primary payer to improve the distribution between 
quartiles. Compared to the 9 unbalanced variables before stratification, the magnitude of 
imbalance was significantly reduced after stratification on propensity scores.  
Table 4.9: Balance on baseline covariates within each quartile 
 Before propensity score 
adjustment 
After propensity score adjustment 
Baseline 
covariates 
Unadjusted p-value Quartiles Adjusted p-value 
Age < 0.0001 1 
2 
3 
4 
0.3987 
0.0155 
0.0027 
0.8103 
Race < 0.0001 1 
2 
3 
4 
0.0061 
0.0007 
< 0.0001 
< 0.0001 
Gender 0.0068 1 
2 
3 
4 
0.0067 
0.2708 
0.3523 
0.8122 
Primary payer < 0.0001 1 
2 
3 
4 
0.0149 
0.9525 
< 0.0001 
0.0166 
Admission 
status 
< 0.0001 1 
2 
3 
4 
< 0.0001 
0.0005 
< 0.0001 
0.0002 
Severity of 
illness 
< 0.0001 1 
2 
3 
4 
0.0004 
0.0002 
0.0655 
0.0002 
Dialysis status < 0.0001 1 
2 
3 
4 
0.2177 
0.1910 
0.2747 
< 0.0001 
Discharge status 0.0003 1 
2 
3 
0.0819 
0.0019 
0.5393 
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4 0.3683 
Physician 
specialty 
< 0.0001 1 
2 
3 
4 
< 0.0001 
< 0.0001 
0.5861 
0.0002 
 
 
Kolmogorov-Smirnov tests for cost values were statistically significant (p-value < 0.001) which 
indicated non-normality with the cost data. This was accounted for by conducting GEE using gamma 
distribution for the cost data. Additionally, no multicollinearity among independent variables was 
found, since the VIF values for none of the variables were greater than 2. Results of the GEE 
estimating total hospital costs, while controlling for propensity quintile are reported in Table 4.10. 
The parameter estimates were exponentiated for interpretation. Figure 4.6 shows the scatter plot of 
Pearson residuals versus predicted value. 
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Table 4.10: GEE estimating total hospital costs, while controlling for propensity quintile 
(dependent variable: total hospital costs) 
Parameter β Exp(β) Standard 
error 
Wald Chi-
square 
p-value 
Intercept 10.314 30162.286 0.0195 279469.926 <0.0001 
Drug group (ESA alone vs 
IV Iron + ESA) 
-0.117 0.89 0.0143 66.275 
 
<0.0001 
Bed size (800 ≥ vs 1-399) 
Bed size (600-799 vs 1-399) 
Bed size (400-599 vs 1-399) 
0.254 
0.226 
0.306 
1.289 
1.254 
1.358 
0.015 
0.0152 
0.0141 
287.316 
219.939 
470.924 
<0.0001 
<0.0001 
<0.0001 
Geographical region 
(Midwest vs West) 
Geographical region 
(Northeast vs West) 
Geographical region 
(Southeast vs West) 
Geographical region 
(Southwest vs West) 
0.007 
 
-0.175 
 
-0.228 
 
-0.029 
1.007 
 
0.840 
 
0.796 
 
0.971 
0.0137 
 
0.014 
 
0.0156 
 
0.0159 
0.293 
 
157.035 
 
215.183 
 
3.332 
0.588 
 
<0.0001 
 
<0.0001 
 
0.068 
Quartile (1 vs 4) 
Quartile (2 vs 4) 
Quartile (3 vs 4) 
0.037 
0.014 
0.028 
1.037 
1.014 
1.029 
0.0118 
0.0114 
0.0114 
9.594 
1.519 
6.209 
<0.0001 
0.147 
0.006 
GEE with gamma distribution and log link and exchangeable correlation structure 
QIC = 83684.698 
QICC = 83675.072 
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Figure 4.6: Scatter plot for testing homoskedasticity for Dependent variable = Total hospital 
costs after GEE with gamma distribution and log link 
 
 
 
According to the GEE model, patients using ESA therapy alone will have 11% lower hospital 
costs than patients using IV iron in addition to ESA, given other things constant. Among 
quartiles, patients in quartile 1 and quartile 3 will have 3.7% and 2.9% higher hospital costs 
compared to the patients in quartile 4. This means that patients with a higher probability of 
receiving IV iron will end up having higher hospital costs than patients with lower probability of 
receiving IV iron. With respect to the hospital level variables, patients admitted to hospitals with 
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large bed capacities were associated with significantly higher (p < 0.0001) hospital costs than 
patients in hospitals with a small bed capacity (1-399). Patients admitted in the hospitals located 
in the Northeast and Southeast regions of the nation will have significantly (p < 0.0001) lower 
costs than the patients admitted to the hospitals located in the Western region of the nation.  
The GEE model predicted an overall mean hospital cost of $ 31,674. The total hospital 
costs for IV iron users and ESA users are presented in Table 4.11. According to the model, a 
patient with anemia of CKD taking IV iron therapy in addition to ESA has an affiliated cost of 
$3,352 more than a patient taking ESA therapy alone 
Table 4.11: Predicted total hospital costs in US dollars 
 Overall IV Iron +ESA therapy ESA therapy alone 
Mean 31674 34756 31404 
Standard Deviation 4114 4598 3956 
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Objective 4: 
Adjusted difference in hospital length of stay by drug group 
 
 
A GEE utilizing a gamma distribution and logarithmic link, clustering for hospitals, was used to 
estimate hospital length of stay while adjusting for potential confounders. 
Kolmogorov-Smirnov tests for cost values were statistically significant (p-value < 0.001) 
which indicated non-normality with the LOS data. This was accounted for by conducting GEE using 
gamma distribution and log link for the LOS data. Additionally, no multicollinearity among 
independent variables was found, since the VIF values for none of the variables were greater than 2. 
Results of the GEE estimating hospital length of stay, while controlling for propensity quintile are 
reported in Table 4.12. The parameter estimates were exponentiated for interpretation. Figure 4.7 
shows the scatter plot of Pearson residuals versus predicted value. 
According to the GEE model, patients using ESA therapy alone will have 14% 
(p<0.0001) lower hospital LOS than patients using IV iron in addition to ESA, given other things 
constant. Among quartiles, patients in quartile 1, 2 and 3 will have 9.9%, 5.1% and 6.5% higher 
hospital length of stay compared to the patients in quartile 4. This means that patients with a 
higher probability of receiving IV iron will end up having longer hospital LOS than patients with 
lower probability of receiving IV iron. With respect to the hospital level variables, patients 
admitted to hospitals with large bed capacities were associated with significantly longer (p < 
0.0001) hospital stay than patients in hospitals with a small bed capacity (1-399). Patients 
admitted in the hospitals located in the Northeast and Southwest regions of the nation will have 
significantly (p < 0.0001) longer hospital stay than the patients admitted to the hospitals located 
in the Western region of the nation.  
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Table 4.12: GEE estimating hospital LOS, while controlling for propensity quintile (dependent 
variable: LOS) 
Parameter β Exp(β) Standard 
error 
Wald Chi-
square 
p-value 
Intercept 2.136 8.467 0.0173 15272.424 < 0.0001 
Drug group (ESA alone vs IV Iron + 
ESA) 
-0.149 0.862 0.0128 135.809 < 0.0001 
Bed size (800 ≥ vs 1-399) 
Bed size (600-799 vs 1-399) 
Bed size (400-599 vs 1-399) 
0.193 
0.144 
0.269 
 
1.212 
1.155 
1.309 
0.0126 
0.0123 
0.0116 
 
234.145 
138.54 
541.858 
 
< 0.0001 
< 0.0001 
< 0.0001 
Geographical region (Midwest vs 
West) 
Geographical region (Northeast vs 
West) 
Geographical region (Southeast vs 
West) 
Geographical region (Southwest vs 
West) 
-0.002 
 
0.092 
 
-0.007 
 
0.232 
0.998 
 
1.096 
 
0.993 
 
1.261 
0.0115 
 
0.0118 
 
0.0129 
 
0.0133 
0.031 
 
60.476 
 
0.291 
 
305.015 
0.86 
 
< 0.0001 
 
0.589 
 
< 0.0001 
Quartile (1 vs 4) 
Quartile (2 vs 4) 
Quartile (3 vs 4) 
0.094 
0.051 
0.066 
1.099 
1.052 
1.069 
0.0102 
0.01 
0.0097 
 
85.253 
25.683 
46.677 
<0.0001 
<0.0001 
<0.0001 
GEE with gamma distribution and log link and exchangeable correlation structure 
QIC = 83684.698 
QICC = 83675.072 
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Figure 4.7: Scatter plot for testing homoskedasticity for Dependent variable = LOS after GEE 
with gamma distribution and log link 
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The GEE model predicted an overall mean hospital LOS of 9.75 days (Table 4.13). The hospital 
length of stay for IV iron users and ESA users are presented in table. According to the model, a 
patient with anemia of CKD taking IV iron therapy in addition to ESA has a LOS of 1 day more 
than a patient taking ESA therapy alone. 
Table 4.13: Predicted hospital LOS in days 
 Overall IV Iron +ESA therapy ESA therapy alone 
Mean 9.75 10.71 9.66 
Standard Deviation 1.25 1.309 1.207 
 
Confirmatory matched cohort analysis 
A matched analysis was done to compare the final estimates for total hospital costs and LOS for 
the two drug user groups with the estimates obtained after using stratification. Optimal (exact) 
matching on propensity score led to a loss of 4158 cases (IV iron users). A matched analysis was 
done on 2324 IV iron users and 2324 ESA users. The total hospital costs incurred by IV iron 
users were $3,802 more than the costs incurred by ESA users and a hospital length of stay of 1.5 
days more than the ESA users. A Wilcoxon signed rank test confirmed these costs to be 
significantly different (p < 0.0001). These results confirm the significant difference in the mean 
hospital costs obtained by the multivariate analysis using stratification on propensity scores.  
Table 4.14: Mean hospital costs and LOS after matching 
 IV Iron +ESA therapy ESA therapy alone 
Variable Mean (SD) Median IQR Mean 
(SD) 
Median IQR p-value 
Total hospital 
costs 
36254 (41058) 20545 10639- 
44941 
32452 
(37960) 
17302 9353-  
38985 
<0.0001 
LOS 11.24 (11.03) 7 4-14 9.76 
(9.98) 
6 4-12 <0.0001 
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CHAPTER 5 
 
Discussion and conclusions 
 
 
Summary of Findings 
 
This chapter summarizes the study, providing discussions on the study results, conclusions 
reached and any limitations. Some suggestions for future research are also presented. 
In this inquiry we attempted to describe the utilization of IV iron and ESA in anemic 
CKD patients, with a focus on understanding predictors of drug use and the overall economic 
impact of drug use on hospital length of stay and total hospital costs.  
Objective 1 explored the utilization of IV iron and ESA therapy in the CKD population. 
Of the 82,497 CKD patients on ESA therapy, only 8% (n = 6678) were on IV iron 
supplementation. Of the 6678 patients on IV iron, 91% were prescribed iron sucrose, and the 
remaining 9% were prescribed iron dextran. The mean ESA days of therapy/100 patient-days 
was 12.36 ±21.92 DOT/100 PDs in the ESA alone group, and 8.66 ± 20.28 in the IV iron therapy 
group with a significant mean difference (p < 0.0001). Within the IV iron group, the mean IV 
iron days of therapy/100 patient-days were 30.41 ± 28.2.  
Objective 2 identified important predictors of IV iron and ESA use within the domains of 
patient demographics, patient clinical characteristics, physician and hospital characteristics. The 
binomial clustered logistic regression results suggest a few predominant themes on the 
demographic traits of patients receiving the IV iron and ESA therapy. Age, race and primary 
payer and physician specialty were identified as strong predictors of IV iron use. Patients 
admitted as emergency cases, with „moderate‟ severity of illness, and not on dialysis are more 
likely to receive IV iron. There exists a strong positive association between total hospital costs, 
LOS, and IV iron use in this population.  
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Objective 3 estimated the total hospital cost in CKD patients using IV iron and ESA 
therapy. According to the multivariate model, the overall mean hospital cost was $ 31,674, which 
can be divided into $ 34,756 for IV iron users and $ 31,404 for ESA users alone. The difference 
in the hospital costs for IV iron users over ESA users was $ 3,352.  
Objective 4 was very similar to objective 3, except the dependent variable was hospital 
length of stay instead of hospital costs. The overall mean LOS was 9.75 days which can be 
broken into 10.71 days and 9.66 days for IV iron and ESA users respectively. The difference was 
approximately 1 day.  
 
Discussion of results by objective 
 
Objective 1 
Descriptive statistics and bar charts were used to understand the prevalence of ESA therapy and 
IV iron supplementation in CKD patients admitted to UHC hospitals. The drug utilization over 
time provides informative data useful for prescribers, hospital administrators, and marketers. 
Studies highlighting changes in drug use are important to measure the impact of events occurring 
in a certain time period that influence such changes.  
Of the 82,497 CKD patients on ESA therapy, only 8% (n = 6678) were on IV iron 
supplementation. Almost 30% of the population was on hemodialysis (n = 25,322); however 
only 8% of the population received IV iron. Previous investigations have found varying 
prevalences of IV iron usage.  Bailie et al. found IV iron being prescribed to 20% of the patients 
with anemia of CKD.
7
 This study included patients from four academic nephrology centers 
where prescribing physicians might have been more familiar with CKD treatment guidelines. 
Rasu et al. examined anemia management patterns in outpatient settings of the US.
52
 Only 3% of 
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the CKD patients with anemia were prescribed IV iron. Reasons for low prevalence of IV iron 
use in this investigation are unclear, particularly because the NKF-KDOQI clinical practice 
guidelines for anemia, which are repeatedly published since 1997, make firm recommendations 
for optimal use of IV iron supplementation in hemodialysis patients. Concerns regarding long 
term safety of IV iron may have had a role in such low prevalence of use. These concerns arise 
from the known effect of iron as a growth factor of bacteria,
127-129
 its suspected inhibition of 
neutrophil function,
130
 and increased oxidative stress leading to atheromatous 
131-133
 change as 
well as anaphylactic and other adverse events associated with the use of IV iron. No large 
prospective clinical trials have investigated the relationship between iron dosing and infectious 
morbidity or mortality. Two observation studies by Feldman et al.
134, 135
 examined the effect of 
IV iron on mortality and hospitalization. The second study evaluated 32,566 hemodialysis 
patients dialyzing at Fresenius Medical Care units during 1996 and 1997. These patients were 
followed up for all-cause mortality through mid-1998. When the time-varying effect of iron 
dosing, lab values and epoetin dosing during 20 months were entered in the multivariable model, 
no significant association between cumulative iron dose and all-cause mortality was observed. 
Results of this report provide cautious support for the safety of the judicious administration of 
cumulative iron doses greater than 1000 mg during 6 months if needed to maintain target Hb 
levels in hemodialysis patients. However, some clinicians may still be reluctant to optimally use 
iron because of lingering concerns about iron toxicity issues.  
A decreasing trend in the use of ESA was observed from the last quarter of 2007 to 2008. 
Looking at the trends in the use of IV iron, a steady increase in prevalence of IV iron use was 
observed from 2006 to 2008. Several events could explain these trends. The National Kidney 
Foundation-Dialysis Outcomes Quality Initiative (NKF-DOQI) revised the clinical practice 
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guidelines for anemia of CKD in 2006. The 2006 NKF-KDOQI clinical practice guidelines 
suggest that a CKD patient‟s hemoglobin (Hb) be checked annually regardless of the cause or 
state of their CKD.
3
 The guidelines firmly recommend providing iron supplementation in order 
to maintain adequate iron indices i.e. transferrin saturation (TSAT) and serum ferritin levels and 
Hb levels. The decreasing trend in ESA use can be a result of all the safety concerns with ESA 
use that have led to the amendment of the labeling of all ESA products by adding a boxed 
warning instructing prescribers to use the lowest dose of ESAs that will gradually increase the 
hemoglobin concentration to the lowest level sufficient to avoid the need for red blood cell 
transfusion.
27
 Also, the FDA recently stated that all ESAs prescribed must be a part of the Risk 
Evaluation and Mitigation Strategies (REMS) program to ensure the safe use of these drugs.
28
  
Of all the patients that got IV iron (n = 6678), more than 90% of the patients were 
prescribed iron sucrose and hardly 9% were prescribed iron dextran. The known risk of 
anaphylactoid and other life-threatening adverse reactions with the use of iron dextran and the 
introduction of safer alternatives may explain the finding of sparse use of iron dextran. However, 
usage of sodium ferric gluconate was not captured in this data. The FDA approved generic iron 
dextran in 1999 and generic iron sucrose in 2004, while sodium ferric gluconate still maintains 
its brand name status. This may explain the lack of sodium ferric gluconate usage within the 
study time frame 
The days of therapy for ESA and IV iron therapy administered to individual patients was 
determined to get a precise understanding of the drug utilization. The mean (±SD) ESA 
DOTs/100 PDs was 12.36 ±21.92 in the ESA group and 8.66 ±20.28 in the IV iron group. T-test 
results showed a statistically significant mean difference of 3.7 [(95% CI = 3.15, 4.24), SE = 
0.278, p < 0.0001]. This finding is consistent with the literature where IV iron use has 
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demonstrated a „dose-sparing‟ effect on ESA use in CKD patients.49, 136  Considering the adverse 
event profile of ESA and the economic challenges associated with its use, reduction in its dose 
and ongoing administration of IV iron can help improve survival rate , quality of life as well as 
provide substantial cost-savings with respect to medication use in CKD patients.  
Although the defined daily dose (DDD) method is recommended by the World Health 
Organization to estimate drug use, important deficiencies of the defined daily dose method 
compared with direct measure of the DOTs have recently been reported.
137-139
 Specifically, the 
defined daily dose method is intended to estimate the DOTs from the quantity of drug purchased 
by the hospital.
140
 In most countries, purchase data are more readily available than measures of 
the DOTs. Electronic capture of pharmacy dispensing and administration data now makes it 
feasible to measure DOTs directly. Moreover, in the UHC data, different hospitals have different 
measurement of units (vial, mg, mcg, ml, units etc), making it difficult to quantify the dose of 
ESA or IV iron therapy using the DDD methodology. DDD methods will underestimate drug 
exposure when the administered daily dose is reduced for a patient with impaired bodily function 
or sudden adverse events. Also, if the administered daily dosage differs significantly from the 
WHO-approved DDD, then DDD methodology will not provide an accurate assessment of the 
number of days of therapy. Days of therapy (DOTs) are the most common alternative measure of 
drug consumption in hospitals.  
 
Objective 2 
A clustered binomial logistic regression using generalized estimating equations (GEE) was used 
to identify potential predictors of IV iron use in anemic CKD patients. Older adults (>= 65 years) 
were significantly more likely to be prescribed IV iron for anemia of CKD compared to young 
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adults in the age range of 18-30 years This finding is consistent with the literature demonstrating 
a high prevalence of IV iron use among older adults.
7
 Race was found to be a strong predictor of 
drug use in the anemic CKD population. The Blacks and the Hispanics were significantly less 
likely to receive IV iron compared to the White population on ESA therapy.  This finding is 
consistent with the current literature.
7,75
 and can be associated to the socioeconomic status of 
these races. Patients covered under the Medicaid, any commercial/private insurance or who paid 
out of pocket for insurance were significantly more likely to receive IV iron therapy as compared 
to patients covered under Medicare. This finding is debatable considering the ambiguity in 
Medicare coverage decisions for ESRD and pre-dialysis CKD patients. Dialysis patients, 
regardless of age, have been entitled to Medicare coverage since 1972.
100
 As a result of 
widespread coverage, Medicare serves as primary insurance for the majority of ESRD patients 
after the initiation of dialysis. Most dialysis patients below the age of 65, however, are not 
eligible for Medicare benefits until the fourth month after initiating dialysis. Medicare does not 
cover any costs of treatment during these first three months of dialysis unless the patient already 
has primary Medicare coverage because of age or disability. The private health plan is the only 
payer for the first three months of dialysis. When a patient becomes eligible for Medicare due to 
ESRD in the fourth month of dialysis, there is a 30 month „coordination period‟ when the health 
plan serves as the primary payer for health care services and Medicare becomes the secondary 
payer. At the end of this 30 month period, Medicare pays for all Medicare covered services as a 
primary payer, and the health plan becomes the secondary payer.
100
 Only 31% of the sample 
CKD population (N = 82,497) was on dialysis, while majority (> 60%) of the patients were pre-
dialysis CKD patients and in the age range of less than 65 years who may not be covered by 
Medicare as their primary payer.  
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Patients admitted to the hospital as emergency and elective cases were significantly more 
likely to be prescribed IV iron as compared to patients admitted to the hospital as urgent cases. 
„Extremely‟ sick CKD patients were less likely to receive IV iron as compared „moderately‟ sick 
patients. This finding can be explained by the concerns physicians may have regarding the use of 
IV iron in terminally ill patients and toxicity issues with IV iron. These concerns arise from the 
known effect of iron as a growth factor of bacteria,
127-129
 its suspected inhibition of neutrophil 
function,
130
 and increased oxidative stress leading to atheromatous 
131-133
 change as well as 
anaphylactic and other adverse events associated with the use of IV iron.  CKD patients on 
dialysis were less likely to receive IV iron as compared to CKD patients not on dialysis. 
However, this finding is unusual considering that IV iron is highly recommended to CKD 
patients on dialysis. As the length of stay increased, CKD patients were more likely to receive IV 
iron. This is reasonable, as the patients‟ length of stay increases, there is a higher likelihood of 
dialysis treatment, and hence requiring IV iron supplementation in addition to ESA therapy.   
With regards to physician specialty, nephrologists were more likely to prescribe IV iron 
to CKD patients already on ESA therapy compared to internal medicine physicians; whereas 
transplant specialists and surgeons were significantly less likely to prescribe IV iron to these 
patients. This finding is consistent with our hypothesis. Recent emphasis has called for early 
referral of CKD patients to nephrologists, since this approach has been demonstrated to improve 
patient outcomes and result in earlier preparation for an initiation of dialysis and prescribe the 
appropriate therapy as needed.
141
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Objective 3 and 4 
A multivariable model clustered by hospitals was used to determine the economic impact of drug 
use (IV iron versus ESA) on total hospital costs and LOS. A propensity score was calculated on 
important baseline covariates. A meta-analyses identified key components necessary for any 
investigation using propensity scores.
142
 Essential components included sufficient events per 
variable (EPV), continuous variable conformity with linear gradient, interactions, 
multicollinearity, assessment of model fit, discrimination of the model, adequate balance 
achieved between the confounders, and adjustment methodology. In a logistic regression model, 
as a rule of thumb, there need to be at least 10 outcomes per variable. This rule has also been 
extrapolated to propensity scores to ensure EPV. This investigation used nine variables for more 
than 80,000 observations. Continuous variable conformity relates to continuous variables used to 
create the propensity score. All the variables used to create the propensity score were categorical. 
No pairwise multicollinearity was found in the model. Fit was assessed using the Quasi-
likelihood under Independence Criterion (QIC) and Corrected Quasi-likelihood under 
Independence Criterion (QICC) was selected for analysis. QIC was used for choosing the best 
working correlation structure assumption, and QICC was used for choosing the best subset of 
predictors in the GEE model. Lower QIC and QICC values imply a better fit model. Assessment 
of fit relates closely to balance between the IV iron and ESA treatment groups. The IV iron and 
ESA groups appeared to be balanced after stratification on propensity scores (Table 4.9). 
Propensity scores from a poorly fit model and without sufficient balance between treatment 
groups can lead to biased estimates of treatment effect.
143
 
Propensity scores can be either used as a continuous variable or stratified into quintiles or 
as a matching factor between the treatment groups. Since there was a sufficient overlap between 
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the IV iron and ESA groups with respect to propensity scores (Figure 4.5), the scores could have 
been used as a continuous variable in the second stage regression model or as a matching factor. 
However, use of propensity score as a continuous variable does not allow any post hoc 
diagnostics to confirm the level of balance achieved, and matching lead to a loss of a significant 
number of cases. In a post hoc fashion, exact one to one matching on propensity scores was 
conducted. Less than 1% change occurred in the parameter estimates for hospital costs and LOS. 
This indicates using the propensity score for stratifying observations was not inappropriate.  
Adjusting for confounders, the overall mean hospital cost was $31,674, which can be 
divided into $ 31,404 for ESA users and $ 34,756 for IV iron users. The difference in ESA over 
IV iron users was $ 3,352. These estimates adjusted for the propensity score quintile and the 
hospital level variables. 
A multivariable model clustered by hospitals was used to determine the economic impact 
of drug use (IV iron versus ESA) on total hospital length of stay. The multivariable model 
adjusted for the propensity quartile and the hospital level variables such as geographical region 
and the bed size. The overall mean LOS was 9.75 days, which can be broken down into 10.71 
days for IV iron and ESA users and 9.66 days for ESA users alone.  
After the multivariable models were calculated for the estimation of hospital costs and 
LOS respectively, an analysis of residuals was conducted. The Pearson residual plots (Figure 4.6 
and 4.7) show a striped pattern instead of a more favorable random scatter. The striped pattern 
was considered a function of the categorical variables used in the regression. On the graphs, the 
Pearson residuals were all small, and there does not seem to be an obvious pattern, except a 
slight downward pattern as the predicted values increase.  
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Practical implications 
This investigation contradicts previous single center analyses that show that IV iron use in 
addition to ESA therapy may lead to cost-savings compared to ESA use alone. The multivariable 
model controlled for known confounders. While controlling for confounders, the predicted 
hospital cost and LOS were still higher for IV iron users versus ESA users alone.  
Why would IV iron users be associated with higher total hospital costs and longer LOS as 
compared to ESA users? The most obvious difference between IV iron and ESA users might be 
the severity of illness. Although this investigation attempted to control for severity of illness 
using the All Patient Refined Diagnosis Related Groups (APR-DRG), there may still have been 
uncontrolled disparity in patients‟ underlying disease status. For example a patient with heart 
failure is not necessarily comparable to a patient with simple iron deficiency anemia. The patient 
with heart failure will most likely be sicker and hence use more resources. However, the APR-
DRG severity of illness index should help control for this dissimilarity. The APR-DRG system is 
an enhancement of the DRG structure and is a good predictor of hospital costs and resource use. 
98, 99
 In this investigation almost 58% of the IV iron users were „majorly‟ sick compared to 54% 
of the ESA users (χ2 = 24.88, df = 2, p-value < 0.0001). In terms of admission status, almost 62% 
of IV iron users were admitted as „emergency‟ patients, compared to 58% of the ESA users (χ2 = 
76.73, df = 2, p-value < 0.0001).  
Incidence of severe adverse events following drug administration, such anaphylaxis, 
cardiac arrest, bronchospasm, coma, shock, allergic reactions can also explain the longer length 
of stay and hence higher total hospital costs. Almost 22% of the IV iron users had one or more 
diagnoses codes for these adverse events related to IV iron use which could lead to a longer stay 
in the hospital and hence higher costs, compared to ESA users. However, the UHC data does not 
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provide dates for diagnoses; hence there is no way to determine if these adverse events followed 
drug administration. 
Further analysis of individual comorbidities revealed a greater proportion of IV iron users 
having comorbidities like congestive heart failure, peripheral vascular disease, hypertension, 
diabetes, chronic pulmonary disease, hypothyroidism, and deficiency anemias, as compared to 
ESA users. As mentioned earlier, individual comorbidities were not included in the regression 
model to avoid multicollinearity with the APR-DRG severity of illness index. A post-hoc 
analysis was performed using the individual comorbidities in the propensity score analysis, 
instead of the APR-DRG severity of illness index. In the second step, multivariate regression 
analysis using the GEE methodology was done to estimate hospital costs and length of stay while 
controlling for the propensity quartile, drug group, hospital level variables and the APR-DRG 
severity of illness index. No significant difference (< 1%) was observed in the final estimates for 
the total hospital costs and LOS. 
The effects of mortality on total hospital costs and LOS merits further discussion. In this 
investigation almost 5% of the ESA users expired in the hospital as compared to 3% of IV iron 
users (χ2 = 14.56, df = 2, p-value = 0.0007). Increased mortality could either increase or decrease 
total hospital costs. If the patient died sooner the hospital stay cost would be truncated. However, 
the patient could have complications prior to death which would lengthen the hospital stay. A 
drawn out hospital stay ending in death could increase the resulting total hospital costs, 
especially if major treatments and procedures were conducted surrounding the end-of-life period. 
Since this investigation had a large sample size, the overall effects of extended and truncated 
LOS were assumed to be minimal.  
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A number of randomized and observational studies have found a low incidence of acute 
reactions to IV iron products.
77,78,144-147
 Longer prospective observations have not clearly 
identified safety issues.
145,148,149
 A cohort study of US dialysis patients showed those billed for > 
10 vials of IV iron dextran (> 1000 mg) over 6 months had an elevated rate of death [adjusted 
relative risk: 1.11; 95% CI (1.00, 1.24)].
134
 A subsequent cohort study used multivariate models 
and accounted for time-varying measures of iron administration as well as other fixed and time-
varying measures of morbidity and found no statistically significant association between any 
level of iron administration and mortality.
135
 Thus, associations between iron administration and 
higher mortality may be confounded. Intravenous iron is hypothesized to increase infection risk, 
although trials have not found an increased infection rate and observational data are 
contradictory.
74
 Some hypothesize that IV iron may contribute to cardiovascular events by 
increasing oxidative stress.
150-152
 Although markers of oxidative stress may be increased by iron, 
observational studies have been contradictory in linking IV iron use to adverse clinical outcomes. 
At usual clinical doses, the dangers of IV iron remain unproven. Thinking about the additional 
day and hospital costs, if one is not looking at individual drug costs, then it is arguably possible 
that using IV iron does not reduce overall hospital length of stay. Also, a hospital stay of one day 
may be statistically significant, but might not have clinical relevance, and the same argument 
might apply to the total hospital costs since the bulk of that maybe attributable to the extra day.  
The results of this study should have good external validity. This was a multi-hospital 
investigation that included 62 hospitals of various sizes and from different geographical regions 
of the country. However the study population was refined to make the ESA and IV iron groups 
as similar as possible with respect to known confounders. The purpose of this data manipulation 
was to isolate the effect of drug use on total hospital costs and length of stay. By excluding 
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outliers the generalizability does decrease. These omissions were necessary to maximize internal 
validity.  
 
Limitations 
Inevitably, there were limitations to this investigation. The first limitation is the difference in 
hospitals with respect to anemia and CKD management policies and formularies/protocols that 
cause variations in hospital cost patterns. However, hospital level factors were used in an attempt 
to control for inter-hospital variability while modeling costs. Also, a clustered analysis using the 
GEE methodology was used to account for nesting of patients within hospitals to control for 
erroneous inferences of associations between independent variables and drug use, total costs and 
length of stay. In the clustered models we put a restriction that patients within a hospital are 
nested and correlated when compared with patients between different hospitals.  
Another potential limitation is the use of cost-to-charge ratios to approximate actual costs 
from hospital charges. Charges are known to inflate the economic burden of hospitalization, 
hence cost-to-charge ratios have been used to better approximate actual cost from charges.
84,85
 
However, this approach may raise some concern as assignment of costs to departments is not 
uniform from hospital to hospital, given the variability of hospital accounting systems, and 
because cost information is often not timely available. In contrast, costs based on relative value 
units are considered more accurate, but they are costly to determine. Schwartz et al evaluated the 
accuracy of costs derived from cost-to-charge ratios by using costs based on relative value units 
as the “gold standard” and concluded that for almost 70 percent of the DRGs, average cost-to-
charge ratios were within 10 percent of the average relative value unit calculated costs. Cost-to-
charge ratios were found to be even more reliable for comparing relative costs for patients in a 
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DRG in one hospital to the average cost for patients in that DRG in a group of hospitals. The use 
of cost-to-charge ratios has shown a correlation with internal accounting costs at a level above 
0.90.
84
 Hence, cost-to-charge ratios can be considered convenient and a straightforward estimate 
of total hospital costs.
84,85
  
Adjusting for underlying severity of illness was a major concern in this investigation.  
There is currently no well-validated severity of illness score for CKD. Other investigations have 
used a variety of techniques including the Stoke Cormobidity Grade (SCG),
91
 the Khan index,
92
 
the Davies index
93
 and the Charlson comorbidity index.
94
 Unlike other indices, the Davies index 
does not include age, because it was specifically designed to be used in conjunction with age as 
an independent covariate. Other comorbidity indices that are in use in studies on ESRD patients 
assign different weights to different comorbidities, such as the Khan or the Charlson index , with 
the weights based on the impact of comorbid diseases on survival.
96
 However, the impact of 
comorbid diseases on survival may be rather different from their impact on health status and 
resource use.
96
 This investigation used the All Patient Refined Diagnosis Related Groups (APR-
DRG) classification system to adjust for severity of underlying illness.
97
 The APR-DRG system 
is an enhancement of the DRG structure and is a good predictor of hospital costs and resource 
use.
98, 99
   
This investigation does not assess the appropriateness of the patients‟ iron 
supplementation therapy. This could raise a concern as costs maybe higher for patients with 
delayed initiation of appropriate therapy. Additionally, differences in IV iron supplementation 
play a role in patients outcomes for CKD anemia.
49
 A cross-sectional study of the US National 
Ambulatory Medical Care Survey (NAMCS) revealed that only 10% of CKD-related visits 
addressing anemia management are receiving anemia medications in US outpatient settings.
52
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This investigation does not evaluate the efficacy of IV iron as an appropriate drug for treating 
anemia in CKD patients. 
This investigation did not examine any patient clinical sub-populations in the 
multivariable analysis. Diabetes, heart failure and hypertension are serious and frequent 
complications of anemia of CKD and hemodialysis. Several studies have been published 
specifically evaluating the economic impact of anemia in CKD patients with chronic heart 
failure.
40,153,154
 This investigation deliberately did not focus on any particular diagnosis sub-
populations in an attempt to increase external validity.  
The database used for this study is derived from a group of university teaching hospitals 
providing tertiary care. University hospitals typically have higher costs, longer LOS and perform 
more complex procedures than community hospitals.
155
 The results from this study may not be 
directly extrapolated to the general hospital community of the U.S. 
Finally, this study used archived inpatient hospital data from the University 
HealthSystem Consortium (UHC). Retrospective data can be convenient since the researcher 
does not have to wait for the data to be prospectively collected. However, invariably problems 
with inadequate or inaccurate codes in databases may introduce bias in the results. Also, 
retrospective analyses depend on data availability. While we have incorporated potential 
predictors from the patient and hospital characteristics, there may be other factors that influence 
the prediction of IV iron use and the resultant hospital costs and length of stay. Factors such as 
physician‟s intent and knowledge level as well as pharmaceutical industry influence, important 
lab values for hemoglobin, transferring saturation, serum ferritin and other iron indices have 
been reported in the literature as possible predictors of IV iron use in anemic CKD patients. 
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However, these factors cannot be assessed, as the database does not provide that information. 
Hence these factors which can contribute to drug use are excluded from the study.  
The UHC consists of all-payer hospital discharge data from most of the nation‟s 
academic medical centers. This database is a rich source of information on key cost components, 
LOS, baseline patient characteristics, and clinical outcomes such as inpatient mortality, 
comorbidities and complication rates.
85
 The Clinical Resource Manager (CRM) database within 
the UHC, provides useful pharmacy data enabling in-depth study of drug utilization patterns in 
several thousands of hospitalized patients. Cost estimates of inpatient care are available for every 
discharge and this information can be aggregated on multiple levels. Hence, in spite of some 
inherent limitations, this database provided as a very useful resource in studying utilization 
patterns of IV iron and ESA and the resultant impact of drug utilization on hospital costs.  
Future research 
The study provides the basis for some interesting future research. Although methodological 
differences (e.g. patient selection, criteria for anemia, dosage calculation) complicate comparison 
of IV iron use in CKD, the prevalence that we found maybe comparable with other recently 
reported prevalences.
7, 52
 Only about 8% of the anemic patients on ESA therapy received IV iron 
supplementation. This low treatment rate represents a major gap in treatment practices and 
signals an opportunity for healthcare improvement. Geographic, demographic, patient clinical 
conditions, physician and hospital level characteristics were explored in this investigation to 
understand IV iron and ESA use and the resultant impact on hospital costs and LOS. Pathologic 
factors, physician practice patterns, pharmaceutical industry influence affecting rates of IV iron 
use in anemia of CKD along with clinical and economic outcomes of such treatment merit 
further research.  
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Our results confirm previous research on ESA dose sparing effect of IV iron use of 
patients on ESA therapy. However, this dose-sparing does not seem to translate into any 
substantial cost-savings in hospitalized CKD patients. Future research should focus on 
understanding the complex relationship between drug use (IV Iron/ESA), hospital length of stay 
and final total hospital costs. Post-dialysis length of stay may be considered an intermediate 
between drug use and hospital costs. The complex relationships involving LOS can be explored 
using advanced analyses like path analysis to tease out why IV iron users seem to cost more than 
ESA users.  
Pharmaceutical industry-effects and their influence on likelihood of IV iron and ESA 
prescribing could be explored. The recently implemented REMS may have a significant impact 
on ESA prescribing and utilization. Influence of such policy related changes on IV iron and ESA 
therapy prescribing would be an interesting area of future research. 
 The safety aspect of IV iron was not in the scope of this study. Longitudinal data on long 
term IV iron utilization with data on important iron indices would be more appropriate to 
understand the incidence of adverse events with the use of IV iron and ESAs and study its 
association with hospital length of stay and total costs. Several publicly available databases such 
as the Freedom of Information surveillance database administered by the US Food and Drug 
Administration (FDA), together with market research data can provide review for the adverse 
event profiles of IV iron preparations available in the US.  
This investigation was conducted from a hospital‟s perspective, and estimated the final 
total hospital costs and length of stay. Further analysis of various component costs such as 
hospitalizations costs, pharmacy costs, physician visits, and laboratory costs, inpatient and 
ambulatory costs can help break down the economic impact of drug use in anemia of CKD. 
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Costs were not able to be sub-categorized in the current study. Only an overall aggregate cost 
was available for each subject since the data came from a large multi-hospital database. 
Finally, the results and suggested conclusions can only be generalized to the IV iron and 
ESA utilization in teaching hospitals. Future studies should look at IV iron and ESA drug use in 
non-teaching and general community hospitals and other settings such as nursing homes, 
community, home health care and compare the results to establish external validity.  
 
Conclusions 
In this inquiry we attempted to describe the utilization of IV iron and ESA in anemic CKD 
patients, with a focus on understanding predictors of drug use and the overall economic impact 
of drug use on hospital length of stay and total hospital costs.  
Analysis of the data collected from 62 teaching hospitals between 2006 and 2008 
highlights the increasing trend in the use of IV iron in anemic CKD patients already on ESA 
therapy. Use of IV iron supplementation lead to a significant decrease in the dose of ESA [3.7, 
95%CI = (3.15, 4.24)]. However, overall prevalence of IV iron (8%) use was very low. Several 
predominant themes were identified on the demographic traits, clinical conditions, physician and 
hospital level characteristics of patients receiving IV iron and ESA therapy. Age, race, primary 
payer, admission status, severity of illness, dialysis status and physician specialty were identified 
as strong predictors of IV iron use in CKD patients.  
The optimal use of IV iron has shown to reduce ESA dose requirements and reduced total 
drug expenditures for anemia management in CKD patients. Our investigation showed 
significant reduction in ESA doses with the use of IV iron supplementation, however, this dose 
reduction did not translate into reduced hospital length of stay and total hospital costs.   
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Multivariate models adjusted for potential confounders estimated $3,352 higher costs and an 
additional day of hospital stay for IV iron users, compared to ESA users. Matched analysis 
confirmed the results obtained by the multivariate models.  
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APPENDIX B 
SAS CODE 
 
 
Propensity score analysis 
 
 
/* Assign appropriate numerical categories to treated/untreated groups*/ 
 
DATA PhD_DATA.Quint_x; 
set PhD_DATA.Quint; 
IF DRUG_GROUP = 'IV_' then DRUG_GROUP = 1; 
if DRUG_GROUP = 'ESA' then DRUG_GROUP = 0; 
run; 
 
 
/*Check for initial differences between IV iron and ESA users */ 
PROC FREQ 
DATA = PhD_DATA.Quint_x; 
TABLES DRUG_GROUP*AGE_GROUP DRUG_GROUP*Sex DRUG_GROUP*Race 
DRUG_GROUP*Admission DRUG_GROUP*Primary_payer DRUG_GROUP*Phys_specialty 
DRUG_GROUP*Dialysis DRUG_GROUP*SOI DRUG_GROUP*DischargeStatus 
DRUG_GROUP*Region DRUG_GROUP*BedSize/ MISSING chisq NOCOL NOROW; 
RUN;  
 
 
/*Calculate propensity scores*/ 
 
proc genmod data = PhD_DATA.Quint_x descending; 
CLASS HCO_ID AGE_GROUP Sex Race Primary_payer Phys_specialty Dialysis 
Admission DischargeStatus SOI; 
model DRUG_GROUP = AGE_GROUP Sex Race Primary_payer Phys_specialty Dialysis 
Admission DischargeStatus SOI / dist=binomial link=log; 
repeated subject = HCO_ID/type = exch; 
OUTPUT OUT= PhD_DATA.final_OBJ7 prob=prob; 
run; 
quit; 
 
 
/*Understand the distribution of the propensity scores between the treatment 
groups*/ 
 
symbol1 v=triangle c = r; 
proc boxplot data=PhD_DATA.final_OBJ7; 
plot prob*DRUG_GROUP / 
boxstyle=skeletal 
vaxis=axis2 
cboxes = bl; 
label prob ='Propensity Score'; 
label DRUG_GROUP ='DRUG_GROUP'; 
RUN; 
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/*Stratification on propensity scores*/ 
 
proc rank data = PhD_DATA.final_OBJ7  groups = 5 out = PhD_DATA.rank; 
ranks rnks; 
var prob; 
run; 
 
data PhD_DATA.quint_x_1; 
set PhD_DATA.rank; 
quintile = rnks +1; 
run; 
 
 
/*Check for balance between treatment groups within each strata*/ 
 
PROC FREQ 
DATA = PhD_DATA.Quint_x_1; 
TABLES quintile*DRUG_GROUP*Race quintile*DRUG_GROUP*Sex 
quintile*DRUG_GROUP*AGE_GROUP quintile*DRUG_GROUP*Primary_payer 
quintile*DRUG_GROUP*Admission quintile*DRUG_GROUP*DischargeStatus 
quintile*DRUG_GROUP*Phys_specialty quintile*DRUG_GROUP*Dialysis 
quintile*DRUG_GROUP*SOI /MISSING chisq NOCOL NOROW; 
run; 
 
 
 
 
Exact/optimal one to one matching on propensity scores 
 
DATA PhD_DATA.Cases PhD_DATA.Control; 
set PhD_DATA.Matching; 
rand_num =uniform(0); 
if cases=1 then output PhD_DATA.Cases; 
else output PhD_DATA.control; 
run; 
 
PROC SQL; 
CREATE table PhD_DATA.abcdef  
as select 
one.RecordId as cases_Id, 
two.RecordId as control_Id, 
one.prob as cases_prob, 
two.prob as control_prob, 
one.rand_num as rand_num 
from PhD_DATA.Cases one, PhD_DATA.Control two 
where (one.prob=two.prob);  
 
 
PROC SORT  
DATA = PhD_DATA.abcdef nodupkey; 
BY control_Id; 
RUN; 
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PROC SORT  
DATA = PhD_DATA.abcdef nodupkey; 
BY cases_Id rand_num; 
RUN; 
 
 
data PhD_DATA.Matching_done PhD_DATA.not_enough; 
set PhD_DATA.abcdef; 
by cases_Id ; 
retain num; 
if first.cases_Id then num=1; 
if num le 2 then do; 
output PhD_DATA.Matching_done; 
num=num+1; 
end; 
if last.cases_Id then do; 
if num le 2 then output PhD_DATA.not_enough; 
end; 
run; 
 
PROC SORT 
DATA = PhD_DATA.Quint_x; 
by RecordId; 
RUN; 
 
DATA PhD_DATA.Case_control (RENAME = (cases_id = RecordId)); 
SET PhD_DATA.casecontrol; 
RUN; 
 
PROC SORT 
DATA = PhD_DATA.Case_control; 
by RecordId; 
RUN; 
 
 
DATA PhD_DATA.MATCH; 
MERGE PhD_DATA.Quint_x (IN=count1)  
 PhD_DATA.Case_control (IN=count2); 
BY RecordId; 
IF count1=1 AND count2=1; 
Run; 
 
PROC SORT 
DATA = PhD_DATA.MATCH; 
BY CASES; 
RUN; 
 
 
 
proc univariate data = PhD_DATA.MATCH; 
by CASES; 
var Hospital_costs LOS; 
run; 
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Generalized estimating equations controlling for propensity quartile and hospital level 
variables 
 
 
/*GEE with gamma distribution and log link to estimate hospital costs*/ 
 
proc genmod data = PhD_DATA.Quint_x_1; 
CLASS DRUG_GROUP quintile Region BedSize HCO_id; 
model Hospital_costs = DRUG_GROUP quintile Region BedSize/ dist=gamma 
link=log; 
repeated subject = HCO_ID/type = exch; 
output out=PhD_DATA.gencook_1 resraw=resraw reschi=reschi 
stdreschi=stdreschi pred=pred resdev=resdev; 
run; 
 
/*Predicted mean costs*/ 
 
proc univariate data = PhD_DATA.gencook_1; 
var pred; 
run; 
proc sort data = PhD_DATA.gencook_1; 
by DRUG_GROUP; 
run; 
proc univariate data = PhD_DATA.gencook_1; 
by DRUG_GROUP; 
var pred; 
run; 
 
/*Plot residuals*/ 
 
proc gplot data=PhD_DATA.gencook_1; 
plot Hospital_costs*pred; 
plot stdreschi * pred; 
plot resraw * pred; 
plot reschi * pred; 
plot resdev * pred; 
run; 
 
 
/*GEE with gamma distribution and log link to estimate hospital LOS*/ 
 
proc genmod data = PhD_DATA.Quint_x_1; 
CLASS DRUG_GROUP quintile Region BedSize HCO_id; 
model LOS = DRUG_GROUP quintile Region BedSize / dist=gamma link=log; 
repeated subject = HCO_ID/type = exch; 
output out=PhD_DATA.gencook_2 resraw=resraw reschi=reschi 
stdreschi=stdreschi pred=pred resdev=resdev; 
run; 
 
/*Predicted mean LOS*/ 
 
proc univariate data = PhD_DATA.gencook_2; 
var pred; 
run; 
proc sort data = PhD_DATA.gencook_2; 
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by DRUG_GROUP; 
run; 
proc univariate data = PhD_DATA.gencook_2; 
by DRUG_GROUP; 
var pred; 
run; 
 
 
/*Plot residuals*/ 
 
proc gplot data=PhD_DATA.gencook_2; 
plot LOS*pred; 
plot stdreschi * pred; 
plot resraw * pred; 
plot reschi * pred; 
plot resdev * pred; 
run; 
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